Luminespib (NVP-AUY922)

Name: Luminespib (NVP-AUY922)
Brand: Selleck Chemicals
SKU: S1069
Rating: 5 (64 reviews)

For research use only.

Catalog No.S1069 Synonyms: AUY-922

64 publications

Luminespib (NVP-AUY922) Chemical Structure

Molecular Weight(MW): 465.54

Luminespib (AUY-922, NVP-AUY922) is a highly potent HSP90 inhibitor for HSP90α/β with IC50 of 13 nM /21 nM in cell-free assays, weaker potency against the HSP90 family members GRP94 and TRAP-1, exhibits the tightest binding of any small-molecule HSP90 ligand. Phase 2.

Selleck's Luminespib (NVP-AUY922) has been cited by 64 publications

Cancer Cell, 2020, 37(3):371-386

PubMed: 32109374 ( click the link to review the publication )

Cancer Cell, 2019, 35(5):752-766

PubMed: 31085176 ( click the link to review the publication )

Nat Med, 2015, 10.1038/nm.3855

PubMed: 25939062 ( click the link to review the publication )

Nat Commun, 2020, 11(1):562

PubMed: 31992715 ( click the link to review the publication )

Genome Med, 2020, 18;12(1):17

PubMed: 32070411 ( click the link to review the publication )

Int J Mol Med, 2020, 45(5):1543-1553

PubMed: 32323753 ( click the link to review the publication )

Exp Lung Res, 2020, 46(6):203-216

PubMed: 32400213 ( click the link to review the publication )

Korean J Physiol Pharmacol, 2020, 1;24(3):241-248

PubMed: 32395075 ( click the link to review the publication )

Nat Commun, 2019, 10(1):402

PubMed: 30679438 ( click the link to review the publication )

J Neurosci, 2019, 39(17):3332-3344

PubMed: 30696728 ( click the link to review the publication )

Cells, 2019, 8(8)

PubMed: 31370342 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(11):2097-2110

PubMed: 31395684 ( click the link to review the publication )

Front Endocrinol (Lausanne), 2019, 10:487

PubMed: 31379752 ( click the link to review the publication )

BMC Cancer, 2019, 19(1):102

PubMed: 30678647 ( click the link to review the publication )

Clin Exp Med, 2019, 10.1007/s10238-019-00587-2

PubMed: 31650359 ( click the link to review the publication )

Hepatology, 2019, 69(2):573-586

PubMed: 29356025 ( click the link to review the publication )

ACS Chem Neurosci, 2019, 10(6):2890-2902

PubMed: 31017387 ( click the link to review the publication )

Transl Lung Cancer Res, 2019, 8(4):340-351

PubMed: 31555510 ( click the link to review the publication )

Autophagy, 2018, 14(6):958-971

PubMed: 29561705 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(24):6548-6555

PubMed: 30154228 ( click the link to review the publication )

Mol Syst Biol, 2018, 14(3):e7858

PubMed: 29507054 ( click the link to review the publication )

J Cell Mol Med, 2018, 22(3):1792-1804

PubMed: 29363851 ( click the link to review the publication )

BMB Rep, 2018, 51(12):660-665

PubMed: 30591093 ( click the link to review the publication )

Cancer Lett, 2017, 411:19-26

PubMed: 28987383 ( click the link to review the publication )
Cancer Chemother Pharmacol, 2017, 80(4):673-684

PubMed: 28779264 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 487(2):313-319

PubMed: 28412368 ( click the link to review the publication )

Onco Targets Ther, 2017, 10:2219-2226

PubMed: 28458565 ( click the link to review the publication )

Sci Rep, 2017, 7(1):201

PubMed: 28298630 ( click the link to review the publication )

Oncotarget, 2017, 8(35):58771-58780

PubMed: 28938595 ( click the link to review the publication )

Cancer Lett, 2016, 372(1):75-81

PubMed: 26723875 ( click the link to review the publication )

Sci Rep, 2016, 6:33710

PubMed: 27641368 ( click the link to review the publication )

J Biol Chem, 2016, 291(19):10332-46

PubMed: 26957545 ( click the link to review the publication )

Horm Cancer, 2016, 7(2):114-26

PubMed: 26858237 ( click the link to review the publication )

PeerJ, 2016, 4:e1683

PubMed: 26893968 ( click the link to review the publication )

Medicinal Chemistry Research, 2016, 10.1007/s00044-016-1553-7

PubMed: ( click the link to review the publication )

Oncotarget, 2016, 7(31):49597-49610

PubMed: 27391062 ( click the link to review the publication )

Immun Inflamm Dis, 2016, 4(4):463-473

PubMed: 27980780 ( click the link to review the publication )

PLoS Negl Trop Dis, 2015, 8(2):e2699

PubMed: 24551261 ( click the link to review the publication )

Biochimica et Biophysica Acta, 2015, 10.1016/j.bbamcr.2015.05.012

PubMed: 25982393 ( click the link to review the publication )

Am J Physiol Lung Cell Mol Physiol, 2015, 309(12):L1410-9

PubMed: 26498249 ( click the link to review the publication )

Int J Biol Sci, 2015, 11(8):923-34

PubMed: 26157347 ( click the link to review the publication )

Molecules, 2015, 20(1):1643-60

PubMed: 25608045 ( click the link to review the publication )

Biochemistry, 2015, 10.1021/acs.biochem.5b00148

PubMed: 25905789 ( click the link to review the publication )

PLoS One, 2015, 10(3):e0119832

PubMed: 25780909 ( click the link to review the publication )

Oncol Lett, 2015, 10(2):941-945

PubMed: 26622600 ( click the link to review the publication )

Oncotarget, 2015, 6(31):31792-804

PubMed: 26397139 ( click the link to review the publication )

Oncoscience, 2015, 2(4):419-427

PubMed: 26097875 ( click the link to review the publication )

Nat Commun, 2014, 5:3361

PubMed: 24553445 ( click the link to review the publication )
Proc Natl Acad Sci USA, 2014, 111(15):E1528-37

PubMed: 24706778 ( click the link to review the publication )

Int J Cancer, 2014, 135(10):2462-74

PubMed: 24706460 ( click the link to review the publication )

PLoS Negl Trop Dis, 2014, 8(2):e2699

PubMed: 24551261 ( click the link to review the publication )

Am J Respir Cell Mol Biol, 2014, 50(1):170-9

PubMed: 23972231 ( click the link to review the publication )

Cell Signal, 2014, 27(2):293-305

PubMed: 25446253 ( click the link to review the publication )

PLoS One, 2014, 9(12):e114506

PubMed: 25503774 ( click the link to review the publication )

Tumour Biol, 2014, 35(8):8193-9

PubMed: 24850175 ( click the link to review the publication )

Mol Oncol, 2013, 7(6):1093-102

PubMed: 23993685 ( click the link to review the publication )

J Biol Chem, 2013, 288(23):16308-20

PubMed: 23599433 ( click the link to review the publication )

J Proteome Res, 2013, 12(8):3697-706

PubMed: 23763277 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2013, 273(2):401-9

PubMed: 24090817 ( click the link to review the publication )

PLoS Pathog, 2012, 8(11):e1003048

PubMed: 23209418 ( click the link to review the publication )

Br J Haematol, 2012, 160(4):465-76

PubMed: 23252346 ( click the link to review the publication )

Mol Cell Biochem, 2012, 370(1-2):141-50

PubMed: 22865466 ( click the link to review the publication )

American Society of Clinical Oncology Annual Meeting, 2012, Chicago

PubMed: ( click the link to review the publication )

Mol Cancer, 2011, 10:125

PubMed: 21962244 ( click the link to review the publication )

Purity & Quality Control

Choose Selective HSP (e.g. HSP90) Inhibitors

Biological Activity

Description

Targets

HSP90α ^[1] (Cell-free assay)	HSP90β ^[1] (Cell-free assay)
13 nM	21 nM

In vitro

NVP-AUY922 inhibits proliferation of various human cancer cell lines in vitro, with an average GI50 of 9 nM. ^[1] The IC50 values of NVP-AUY922 fall in the range of 2 to 40 nM in these gastric cancer cell lines. IC50 value for the BEAS-2B cells is 28.49 nM. Treatment with NVP-AUY922 does not influence the expression of HSP90, but expression of HSP70 gets elevated by NVP-AUY922 treatment. NVP-AUY922 increases the binding of HSP70 to HSP90. NVP-AUY922 causes p23 dissociation from the HSP90 complex and can then recruit HSP70 to the HSP90 complex. ^[1] After the treatment with NVP-AUY922, expression of receptor tyrosine kinases including VEGFR1, 2, 3 and PDGFRɑ is decreased. A decrease is also noticed in the expression of Akt and phospho-Akt. Meanwhile, treatment with NVP-AUY922 causes decreased expression of HER-2 in NCI-N87 cells. NVP-AUY922 treatment results in binding of HSP90 to client proteins and setting them up as targets for degradation by the proteasome. NVP-AUY922 can influence cell growth by affecting multiple signaling pathways. In addition, treatment with the proteasome inhibitor, MG132, restores expression of thymidylate synthase, which is decreased by NVP-AUY922. NVP-AUY922 increases the expression of cleaved caspase-3 leading to apoptosis in HSC-2 cells.^[1]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
CMK	MkS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MljXTWM2OD1yLkCwNFEzPSEQvF2=	M2q0N3NCVkeHUh?=
MV-4-11	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mm\sTWM2OD1yLkCwNFU2QCEQvF2=	NFrRXXhUSU6JRWK=
NALM-6	NGPyblhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mk\WTWM2OD1yLkCwNFg1OiEQvF2=	MUHTRW5ITVJ?
HOS	M2[5cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV7obVh[UUN3ME2wMlAxOTN6IN88US=>	M{fzVXNCVkeHUh?=
HT-144	NHH1RnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGPVV2JKSzVyPUCuNFAyPTVizszN	NVzFZpJVW0GQR1XS
SW1710	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MU\JR\|UxRTBwMECxPFYh\|ryP	M{jsNnNCVkeHUh?=
TE-8	NUHrS451T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFHXW\|JKSzVyPUCuNFAzOzdizszN	MXfTRW5ITVJ?
ES1	NG\qUmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2HUWmlEPTB;MD6wNFI3PiEQvF2=	M2DVd3NCVkeHUh?=
CCF-STTG1	NH7BfGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4HiNmlEPTB;MD6wNFI6PyEQvF2=	M2HF[3NCVkeHUh?=
PSN1	MmDhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1flcWlEPTB;MD6wNFMyQCEQvF2=	NGi4fmRUSU6JRWK=
CAL-51	M3rDOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVvJR\|UxRTBwMECzNlUh\|ryP	M4\O[XNCVkeHUh?=
MCF7	MlG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkLqTWM2OD1yLkCwN\|M2KM7:TR?=	NIK1boJUSU6JRWK=
SK-HEP-1	Mki2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmLoTWM2OD1yLkCwN\|M3KM7:TR?=	NUTPRlFrW0GQR1XS
LCLC-103H	NGfBb4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIrzR3BKSzVyPUCuNFA1OyEQvF2=	MYLTRW5ITVJ?
HMV-II	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYfJR\|UxRTBwMEC0OFkh\|ryP	NF7KdlRUSU6JRWK=
MES-SA	NXns[4lCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYTJR\|UxRTBwMEC0OVIh\|ryP	NX\vcGJ1W0GQR1XS
SK-LMS-1	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmKxTWM2OD1yLkCwOFU5KM7:TR?=	NUWyUIZYW0GQR1XS
639-V	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnLPTWM2OD1yLkCwOFg2KM7:TR?=	NVjUfGo5W0GQR1XS
SIG-M5	MoOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml7wTWM2OD1yLkCwOFg6KM7:TR?=	M3;Xb3NCVkeHUh?=
LOUCY	MoPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGnGSXBKSzVyPUCuNFA2ODVizszN	NYXYeFlXW0GQR1XS
HSC-2	NYX0OpBLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmmwTWM2OD1yLkCwOVE5KM7:TR?=	M{\vbHNCVkeHUh?=
EW-13	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFHNbJZKSzVyPUCuNFA2OThizszN	NWnZWnA5W0GQR1XS
RT-112	Ml\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYLYOY5bUUN3ME2wMlAxPTN3IN88US=>	NELkd2hUSU6JRWK=
NKM-1	NXrIN2c1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGLZdHhKSzVyPUCuNFA2PDdizszN	MlzoV2FPT0WU
KYSE-180	MmfxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MULJR\|UxRTBwMEC1PFYh\|ryP	NGnzT\|FUSU6JRWK=
SW1783	NFHmWndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M33EUGlEPTB;MD6wNFU6OSEQvF2=	NIH1SphUSU6JRWK=
A431	NYrmT3BZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXfJR\|UxRTBwMEC2NFch\|ryP	MnPkV2FPT0WU
SK-OV-3	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYTxUolTUUN3ME2wMlAxPjNizszN	MmjQV2FPT0WU
RPMI-7951	MlvqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4jUOGlEPTB;MD6wNFY{OSEQvF2=	MnG1V2FPT0WU
Capan-2	M3:yZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVGxNlBbUUN3ME2wMlAxPjN6IN88US=>	M1\HUHNCVkeHUh?=
HSC-3	M4TkNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnHKTWM2OD1yLkCwOlQyKM7:TR?=	M1ThVnNCVkeHUh?=
786-0	NWOzbHF3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4rlOWlEPTB;MD6wNFY3OyEQvF2=	NIHmcWVUSU6JRWK=
Daoy	MnO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF;3coFKSzVyPUCuNFA3QTVizszN	MUDTRW5ITVJ?
KGN	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH\VfXlKSzVyPUCuNFA4ODNizszN	NFfIUHlUSU6JRWK=
EW-16	NHHIUY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1:2UWlEPTB;MD6wNFc1QSEQvF2=	MnnmV2FPT0WU
EW-7	NWXJUFRUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWjJR\|UxRTBwMEC3OVQh\|ryP	M3r6UXNCVkeHUh?=
IGROV-1	NHX2[5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2PCPWlEPTB;MD6wNFgyPCEQvF2=	M{LuZ3NCVkeHUh?=
8505C	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlXtTWM2OD1yLkCwPFIyKM7:TR?=	NVfqfm85W0GQR1XS
RKO	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWXJR\|UxRTBwMEC4NlYh\|ryP	NEX6VZRUSU6JRWK=
GDM-1	NVPSbINKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWjJR\|UxRTBwMEC4OEDPxE1?	NHjzd\|JUSU6JRWK=
IST-MEL1	Mm\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVvJR\|UxRTBwMEC4OVIh\|ryP	M3j6c3NCVkeHUh?=
RPMI-6666	M2TLXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoLPTWM2OD1yLkCwPFUzKM7:TR?=	NEexZlhUSU6JRWK=
SNG-M	M3ywU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmDZTWM2OD1yLkCwPFU3KM7:TR?=	NITtNHZUSU6JRWK=
KS-1	NVvYfmJLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlfzTWM2OD1yLkCwPFU6KM7:TR?=	NV\mfmVHW0GQR1XS
RXF393	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MknnTWM2OD1yLkCwPFYh\|ryP	M{\N[HNCVkeHUh?=
CAL-12T	NHf3TFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVG0UZNxUUN3ME2wMlAxQTJ{IN88US=>	NXfCTXhDW0GQR1XS
BFTC-905	NI\QNnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXfJR\|UxRTBwMEC5N\|gh\|ryP	M2rhbnNCVkeHUh?=
SK-MES-1	NX\Lem1WT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NU\6UXEyUUN3ME2wMlAxQTR3IN88US=>	NUiyXZc5W0GQR1XS
BB30-HNC	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3[4dmlEPTB;MD6wNFk2OiEQvF2=	M4PTTHNCVkeHUh?=
AN3-CA	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M364VGlEPTB;MD6wNVAyPyEQvF2=	NEjVNHFUSU6JRWK=
EFO-27	MoqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXW2R5RbUUN3ME2wMlAyODF5IN88US=>	NHrkUVdUSU6JRWK=
G-401	NGm5dYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{DDSWlEPTB;MD6wNVAzPSEQvF2=	M3TzOnNCVkeHUh?=
BPH-1	M3\OV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NG\4SFRKSzVyPUCuNFExOyEQvF2=	NH\CXYdUSU6JRWK=
NCI-H727	M3fjR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3nPTWlEPTB;MD6wNVA{KM7:TR?=	NGXJboJUSU6JRWK=
SNU-423	Mn21S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWnJR\|UxRTBwMEGwOVMh\|ryP	NETje4lUSU6JRWK=
KYSE-270	NFfNOY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlzhTWM2OD1yLkCxNFU6KM7:TR?=	NWHnOpo4W0GQR1XS
AGS	MlHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkT6TWM2OD1yLkCxNFYyKM7:TR?=	NF7XUXdUSU6JRWK=
NCI-H2228	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXzWe403UUN3ME2wMlAyODZ2IN88US=>	M{TtOnNCVkeHUh?=
SW954	M3O5[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGHm[4tKSzVyPUCuNFExPzFizszN	M1e2NnNCVkeHUh?=
769-P	MmKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mnm3TWM2OD1yLkCxNFc{KM7:TR?=	NVfFNWhmW0GQR1XS
BB49-HNC	NWPFUY1VT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUiz[YFYUUN3ME2wMlAyODd5IN88US=>	NY\FU4lVW0GQR1XS
IA-LM	MlfGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGP4W4pKSzVyPUCuNFExQDZizszN	MnT5V2FPT0WU
NB69	M2L3OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX3NOpZ1UUN3ME2wMlAyOTB{IN88US=>	MYjTRW5ITVJ?
C8166	NHLFZVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3zNb2lEPTB;MD6wNVEzQSEQvF2=	M3yw[nNCVkeHUh?=
NCI-H1299	NH\icIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmHyTWM2OD1yLkCxNVU1KM7:TR?=	NGXncXpUSU6JRWK=
YKG-1	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmC3TWM2OD1yLkCxNVYh\|ryP	M1q3SHNCVkeHUh?=
PANC-03-27	NIS5TFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV:1V25VUUN3ME2wMlAyOTZ{IN88US=>	M2XINHNCVkeHUh?=
YT	NHrGR5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoPOTWM2OD1yLkCxNVc6KM7:TR?=	M2XsW3NCVkeHUh?=
CAL-85-1	NFLQbllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWXUcYJMUUN3ME2wMlAyOTl{IN88US=>	NYP1RmdEW0GQR1XS
GT3TKB	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2TwPGlEPTB;MD6wNVIxOiEQvF2=	NV62V4JvW0GQR1XS
BB65-RCC	NXr5fGxQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUXYdnpvUUN3ME2wMlAyOjB2IN88US=>	MU\TRW5ITVJ?
ES6	NHXOW2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4naZmlEPTB;MD6wNVI3OSEQvF2=	M1\kTXNCVkeHUh?=
MHH-ES-1	NHi4[GdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH\sUJdKSzVyPUCuNFEzPjNizszN	NFnreIdUSU6JRWK=
QIMR-WIL	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV3JR\|UxRTBwMEGyOlkh\|ryP	MonNV2FPT0WU
SNU-C2B	M3;2[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXjJR\|UxRTBwMEGyO\|Ih\|ryP	MnTGV2FPT0WU
OCI-AML2	MmftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NY\RfplDUUN3ME2wMlAyOjhzIN88US=>	MnO1V2FPT0WU
DU-145	NFnmcZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYTDblRGUUN3ME2wMlAyOjlizszN	MXLTRW5ITVJ?
SW982	MoTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWnJR\|UxRTBwMEGyPVMh\|ryP	NX;NV2NNW0GQR1XS
MFH-ino	M1;4fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVPJR\|UxRTBwMEGyPVMh\|ryP	Mn;yV2FPT0WU
A427	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFj0UVlKSzVyPUCuNFEzQTlizszN	MUDTRW5ITVJ?
LCLC-97TM1	NWTOTphFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4jXdmlEPTB;MD6wNVMh\|ryP	NEGz[4pUSU6JRWK=
AM-38	MoDjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH7CUI5KSzVyPUCuNFE{ODJizszN	MnjmV2FPT0WU
K5	MoLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFO3elFKSzVyPUCuNFE{ODhizszN	M{\ZN3NCVkeHUh?=
T84	Mn[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{DyR2lEPTB;MD6wNVM{OSEQvF2=	Mk\xV2FPT0WU
TE-15	NEDRUVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlHrTWM2OD1yLkCxN\|M3KM7:TR?=	MlexV2FPT0WU
NCI-H460	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NITlOYxKSzVyPUCuNFE{OzZizszN	NX3qO3lpW0GQR1XS
NTERA-S-cl-D1	MnfMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3iyWGlEPTB;MD6wNVM{QSEQvF2=	Mn3DV2FPT0WU
KYSE-450	M{D4T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NULIT\|N3UUN3ME2wMlAyOzR7IN88US=>	NVTRT4c{W0GQR1XS
H4	NFH5bIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVfiZZNYUUN3ME2wMlAyOzZ4IN88US=>	NUHyVHdTW0GQR1XS
LC-2-ad	NH\oSpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVPJb5pTUUN3ME2wMlAyOzdizszN	M2jHbXNCVkeHUh?=
GAMG	NEXP[oJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFH2UmhKSzVyPUCuNFE{PzFizszN	MWDTRW5ITVJ?
TK10	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYTJR\|UxRTBwMEGzPFIh\|ryP	MmTLV2FPT0WU
NCI-H2122	MkjBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3T4bGlEPTB;MD6wNVM5PCEQvF2=	NHjmdnBUSU6JRWK=
KM12	NGPiSYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX7JR\|UxRTBwMEGzPVkh\|ryP	M3XJZ3NCVkeHUh?=
CAL-39	M2rGfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4KzTGlEPTB;MD6wNVQzKM7:TR?=	MWLTRW5ITVJ?
RPMI-2650	NEnUPJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml75TWM2OD1yLkCxOFMzKM7:TR?=	M3HUcXNCVkeHUh?=
KYSE-510	NF\BeI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mlz1TWM2OD1yLkCxOFQzKM7:TR?=	NITYNI5USU6JRWK=
KALS-1	MoPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVHJR\|UxRTBwMEG0OlYh\|ryP	MmrUV2FPT0WU
NCI-H1648	NWTLUHRyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NITZT3JKSzVyPUCuNFE1QTlizszN	NFLCSWlUSU6JRWK=
ES4	NW[4XG9HT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFS5d2tKSzVyPUCuNFE2ODJizszN	NELDcpNUSU6JRWK=
C-33-A	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXvJR\|UxRTBwMEG1NFkh\|ryP	NEnvWW5USU6JRWK=
MIA-PaCa-2	M{Gwe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYLGOGo2UUN3ME2wMlAyPTB7IN88US=>	MWXTRW5ITVJ?
Becker	NEHGdI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3HLT2lEPTB;MD6wNVUyPCEQvF2=	MWjTRW5ITVJ?
HOP-62	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUDOfW06UUN3ME2wMlAyPTR{IN88US=>	NWHpSXlEW0GQR1XS
TE-1	M1PRfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmLCTWM2OD1yLkCxOVgyKM7:TR?=	M2X5UXNCVkeHUh?=
KYSE-410	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYLLOo1yUUN3ME2wMlAyPTh4IN88US=>	MlezV2FPT0WU
NOS-1	NY\oc2pJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXrJR\|UxRTBwMEG1PVMh\|ryP	NE\E[INUSU6JRWK=
MEL-HO	M1fycWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV20Vm02UUN3ME2wMlAyPjR\|IN88US=>	Mo\KV2FPT0WU
NCI-H1650	MoruS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mlm5TWM2OD1yLkCxOlQ3KM7:TR?=	NUPFbIFHW0GQR1XS
VMRC-RCZ	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGOzbo1KSzVyPUCuNFE3PTFizszN	MWPTRW5ITVJ?
HuP-T3	NU\xTFM1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnfRTWM2OD1yLkCxOlU{KM7:TR?=	NEjPOY9USU6JRWK=
ACN	NXjkNWZxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlPiTWM2OD1yLkCxOlU4KM7:TR?=	M2fDSXNCVkeHUh?=
MEL-JUSO	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFexNXRKSzVyPUCuNFE3QDFizszN	NUjZ[W9CW0GQR1XS
HT-1197	NGfUUWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF3nZY9KSzVyPUCuNFE3QDVizszN	NFv0c3FUSU6JRWK=
NCI-H2030	M3Xzc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml\BTWM2OD1yLkCxOlk4KM7:TR?=	M2[wT3NCVkeHUh?=
A4-Fuk	NV\5[\|BUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUfJR\|UxRTBwMEG3NFIh\|ryP	MX3TRW5ITVJ?
NCI-H292	NEjYNVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEjxR3lKSzVyPUCuNFE4ODlizszN	NFOzXIxUSU6JRWK=
A2780	NVrUdmlUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnW5TWM2OD1yLkCxO\|E2KM7:TR?=	MlXqV2FPT0WU
SF295	M2\vPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUPJR\|UxRTBwMEG3NlEh\|ryP	MlTkV2FPT0WU
NCI-H810	NEnKeHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXnJR\|UxRTBwMEG3NlQh\|ryP	NE\GRm5USU6JRWK=
ALL-PO	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3e0cmlEPTB;MD6wNVc{PSEQvF2=	M3e1fXNCVkeHUh?=
MC-IXC	M3vOSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlSxTWM2OD1yLkCxO\|M3KM7:TR?=	NIXDRlFUSU6JRWK=
NY	M17WZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NU\yVJJwUUN3ME2wMlAyPzRizszN	NEL4Sm5USU6JRWK=
OMC-1	M2jOV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlnpTWM2OD1yLkCxO\|UyKM7:TR?=	NHvGblJUSU6JRWK=
PANC-10-05	M4HtbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVHJR\|UxRTBwMEG3OVUh\|ryP	M3ryXHNCVkeHUh?=
NCI-H2342	M3XtT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnfrTWM2OD1yLkCxO\|U5KM7:TR?=	Ml7kV2FPT0WU
HGC-27	NWjafWVrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYC2XHlWUUN3ME2wMlAyPzV6IN88US=>	MX;TRW5ITVJ?
TE-12	MlPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFjHPY9KSzVyPUCuNFE4PzVizszN	M{T6RnNCVkeHUh?=
MOLT-16	NIGzeZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M13zT2lEPTB;MD6wNVc5QCEQvF2=	MXrTRW5ITVJ?
HL-60	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NI\hN5FKSzVyPUCuNFE5ODdizszN	M2rHXHNCVkeHUh?=
OVCAR-5	NHG3V2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUfsZVA2UUN3ME2wMlAyQDF{IN88US=>	NIHN[JlUSU6JRWK=
SK-LU-1	NGjL[VNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3vaeGlEPTB;MD6wNVg1PiEQvF2=	NEnmXVJUSU6JRWK=
MG-63	MoDmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3vDOGlEPTB;MD6wNVg4PCEQvF2=	M{fMbnNCVkeHUh?=
8-MG-BA	NUfDXWdST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYHJR\|UxRTBwMEG4PFQh\|ryP	MYnTRW5ITVJ?
COR-L105	M4n0b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlrSTWM2OD1yLkCxPVEyKM7:TR?=	NUfBWmtWW0GQR1XS
BHY	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mo\wTWM2OD1yLkCxPVEzKM7:TR?=	MXLTRW5ITVJ?
SW620	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEPsNmNKSzVyPUCuNFE6OTVizszN	NEn5VIVUSU6JRWK=
PC-14	M{Pncmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXfGNYxqUUN3ME2wMlAyQTN2IN88US=>	MojSV2FPT0WU
NCI-H522	NFLENYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoH6TWM2OD1yLkCxPVM6KM7:TR?=	M4K0UHNCVkeHUh?=
OE19	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1XDTGlEPTB;MD6wNVk2KM7:TR?=	MoLvV2FPT0WU
RVH-421	NYjCNIhQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXTNdJBvUUN3ME2wMlAyQTV5IN88US=>	M{[2cXNCVkeHUh?=
TE-10	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlvZTWM2OD1yLkCxPVc4KM7:TR?=	MXHTRW5ITVJ?
A101D	NW\HfVhnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYXqeJo3UUN3ME2wMlAyQTh5IN88US=>	M{PtfnNCVkeHUh?=
HUTU-80	MoL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVyySW93UUN3ME2wMlAzODB2IN88US=>	NXHpZYl6W0GQR1XS
KYSE-140	M2\oWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlPkTWM2OD1yLkCyNFI1KM7:TR?=	NEfLTI5USU6JRWK=
SNU-449	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2L5[mlEPTB;MD6wNlAzPiEQvF2=	NEHB[\|FUSU6JRWK=
697	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVnxZXZzUUN3ME2wMlAzODNzIN88US=>	MXXTRW5ITVJ?
SJSA-1	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3L3RWlEPTB;MD6wNlA{PyEQvF2=	MXHTRW5ITVJ?
IGR-1	NX3FbGJvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4\hXmlEPTB;MD6wNlA2KM7:TR?=	MVrTRW5ITVJ?
GCIY	M2Pu[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFLJNWRKSzVyPUCuNFIxPTVizszN	M13hXHNCVkeHUh?=
REH	Mn:0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXztNlYyUUN3ME2wMlAzODV7IN88US=>	NITGT5VUSU6JRWK=
A204	NWjZUYwxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH7meo9KSzVyPUCuNFIyOTVizszN	MUTTRW5ITVJ?
A388	Mn\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoXFTWM2OD1yLkCyNVE2KM7:TR?=	M{f2[XNCVkeHUh?=
NCI-H650	Ml\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmHCTWM2OD1yLkCyNVE4KM7:TR?=	MUPTRW5ITVJ?
SW626	M1rISGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnnDTWM2OD1yLkCyNVIh\|ryP	NVTlbpVbW0GQR1XS
DoTc2-4510	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NISyN3hKSzVyPUCuNFIyOjJizszN	NHjaOYZUSU6JRWK=
HCE-4	NGi1eY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4\6W2lEPTB;MD6wNlE1PSEQvF2=	MXjTRW5ITVJ?
DU-4475	M2PHc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlK4TWM2OD1yLkCyNVUh\|ryP	NFT2S4lUSU6JRWK=
A375	NV\NNoVCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWPLU\|BbUUN3ME2wMlAzOTdzIN88US=>	M4\4TXNCVkeHUh?=
GB-1	M2H4Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MY\JR\|UxRTBwMEKxPFgh\|ryP	NH73enpUSU6JRWK=
CHP-212	MkOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1LqWmlEPTB;MD6wNlIyOiEQvF2=	MXPTRW5ITVJ?
HT-1080	NGLvSlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{jVPWlEPTB;MD6wNlIyPCEQvF2=	MknEV2FPT0WU
M059J	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{LYTWlEPTB;MD6wNlI1OSEQvF2=	NIPDTW9USU6JRWK=
NMC-G1	MnHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3TjO2lEPTB;MD6wNlI5KM7:TR?=	NYf4cYhrW0GQR1XS
MRK-nu-1	M4m4eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NY\J[VFmUUN3ME2wMlAzOyEQvF2=	NWDnW2JXW0GQR1XS
MFE-296	NF;lSnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFTUbWpKSzVyPUCuNFI{OjJizszN	MmTFV2FPT0WU
LOXIMVI	M4XNS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3v1W2lEPTB;MD6wNlMzOyEQvF2=	NEfKVYxUSU6JRWK=
CGTH-W-1	NEnTcIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXfwdXE6UUN3ME2wMlAzOzJ6IN88US=>	NXrtdXhqW0GQR1XS
CCRF-CEM	M{G4N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1rybmlEPTB;MD6wNlMzQSEQvF2=	Mlz4V2FPT0WU
ACHN	NH7iW2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH;KZm1KSzVyPUCuNFI{PDVizszN	MoH1V2FPT0WU
NCI-H1355	NIrYZW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3fIOWlEPTB;MD6wNlQxOSEQvF2=	MnfZV2FPT0WU
NCI-H1651	NV32WoNmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml63TWM2OD1yLkCyOFMyKM7:TR?=	MXnTRW5ITVJ?
KINGS-1	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnHpTWM2OD1yLkCyOFM{KM7:TR?=	MVLTRW5ITVJ?
LS-123	NY\XempZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MojKTWM2OD1yLkCyOFM2KM7:TR?=	MVXTRW5ITVJ?
SNB75	MnHsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXywO5lvUUN3ME2wMlAzPDZ4IN88US=>	MX\TRW5ITVJ?
C3A	NGXKV21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFXkXFdKSzVyPUCuNFI1PzVizszN	NULFZ2h7W0GQR1XS
HO-1-N-1	NGDWemtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIjHeG9KSzVyPUCuNFI2PDlizszN	M4HFeHNCVkeHUh?=
EHEB	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYnm[\|lqUUN3ME2wMlAzPTV3IN88US=>	NWTWNGVrW0GQR1XS
CAL-62	NF;KSnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVLJR\|UxRTBwMEK1O{DPxE1?	M2rMRXNCVkeHUh?=
U-118-MG	MnXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnjpTWM2OD1yLkCyOVc3KM7:TR?=	MkHXV2FPT0WU
HN	MkH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3LoU2lEPTB;MD6wNlU6OyEQvF2=	NFG5NFFUSU6JRWK=
HTC-C3	MlK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYDzUo5JUUN3ME2wMlAzPjB5IN88US=>	M2HLUnNCVkeHUh?=
KYSE-520	M1LiV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXTWVXRXUUN3ME2wMlAzPjF\|IN88US=>	NVTHdHNTW0GQR1XS
MZ1-PC	Mmq5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlfoTWM2OD1yLkCyOlM6KM7:TR?=	MknSV2FPT0WU
BCPAP	MnHWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mo\YTWM2OD1yLkCyOlQ3KM7:TR?=	NFf5NY9USU6JRWK=
RD	NFP3V\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVfJR\|UxRTBwMEK2OVgh\|ryP	NEXNT4xUSU6JRWK=
NCI-H520	NHjVRW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEfiZ\|hKSzVyPUCuNFI3PjRizszN	MnfoV2FPT0WU
LXF-289	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGPXWlZKSzVyPUCuNFI3PjhizszN	MUXTRW5ITVJ?
G-361	MofUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWPJR\|UxRTBwMEK2O\|ch\|ryP	MoDPV2FPT0WU
LB996-RCC	NFzqVG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NET2RnVKSzVyPUCuNFI4OSEQvF2=	MoS2V2FPT0WU
COR-L23	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWn2VpFvUUN3ME2wMlAzPzF\|IN88US=>	M2DmOnNCVkeHUh?=
GP5d	MnfBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mnv1TWM2OD1yLkCyO\|I{KM7:TR?=	NUHR[YpSW0GQR1XS
SW1990	NYDGZoVUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVHJR\|UxRTBwMEK3NlQh\|ryP	NYW0fG1pW0GQR1XS
PA-1	NIrUfFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnPqTWM2OD1yLkCyO\|U2KM7:TR?=	NV;m[ZVqW0GQR1XS
NCI-H2009	M1;oRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnvkTWM2OD1yLkCyO\|Yh\|ryP	NXzvWJFwW0GQR1XS
SR	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYPJR\|UxRTBwMEK3PFUh\|ryP	NH;LU3ZUSU6JRWK=
Ca9-22	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkLMTWM2OD1yLkCyO\|k3KM7:TR?=	MXrTRW5ITVJ?
SCC-15	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3jUZWlEPTB;MD6wNlgxOSEQvF2=	NVnpZnVZW0GQR1XS
ETK-1	MnzVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFfVOFdKSzVyPUCuNFI5ODZizszN	MW\TRW5ITVJ?
SCC-4	NUXjenNIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mnj5TWM2OD1yLkCyPFA6KM7:TR?=	MkDKV2FPT0WU
5637	Mkf4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVXGZW9IUUN3ME2wMlAzQDJ{IN88US=>	MVXTRW5ITVJ?
EW-1	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmS3TWM2OD1yLkCyPFIzKM7:TR?=	NIDBeZpUSU6JRWK=
SW962	NVfyblZZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHXUWmhKSzVyPUCuNFI5PTJizszN	NHLWPINUSU6JRWK=
HCE-T	NH3tW5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIOwS4FKSzVyPUCuNFI5PiEQvF2=	NHn6SmJUSU6JRWK=
NCI-H2405	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIXkc5dKSzVyPUCuNFI5QDdizszN	NWPRW3dDW0GQR1XS
A2058	Mo\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEfCcGtKSzVyPUCuNFI6OjlizszN	MX;TRW5ITVJ?
HCC2998	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mo[4TWM2OD1yLkCyPVQ2KM7:TR?=	NW\vWYxbW0GQR1XS
ONS-76	M4DFeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVLWbpJxUUN3ME2wMlAzQTV2IN88US=>	MkT1V2FPT0WU
DBTRG-05MG	NGjK[\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlrlTWM2OD1yLkCyPVU2KM7:TR?=	NILROo9USU6JRWK=
HuCCT1	NGXIenZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1znRmlEPTB;MD6wNlk3OSEQvF2=	NFLBe2VUSU6JRWK=
J82	M2rzTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUfJR\|UxRTBwMEOwNFch\|ryP	MknUV2FPT0WU
MKN28	MoTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoWwTWM2OD1yLkCzNFEzKM7:TR?=	NEjR[opUSU6JRWK=
SW837	NGTRdWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXnJR\|UxRTBwMEOwNVQh\|ryP	MUDTRW5ITVJ?
no-10	NWriUGl6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MU\JR\|UxRTBwMEOwNVYh\|ryP	MUfTRW5ITVJ?
BC-3	NGXmTo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4m1WmlEPTB;MD6wN\|AyQCEQvF2=	NYm2U2ZnW0GQR1XS
no-11	NYHS[JJbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGn3T3lKSzVyPUCuNFMxPDhizszN	NHjXPHVUSU6JRWK=
8305C	NFH0WXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXvCS4ZUUUN3ME2wMlA{ODd{IN88US=>	M{O2PHNCVkeHUh?=
COLO-679	M4f5W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2WzSWlEPTB;MD6wN\|ExPyEQvF2=	MmPQV2FPT0WU
CESS	M3TlbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX3JR\|UxRTBwMEOxNkDPxE1?	NEjpdXRUSU6JRWK=
BFTC-909	M{Ppb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVPJR\|UxRTBwMEOxNlUh\|ryP	Ml3jV2FPT0WU
MZ2-MEL	M3;wPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVXJR\|UxRTBwMEOxO\|ch\|ryP	NETBWmNUSU6JRWK=
SW872	NFHqfXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmnYTWM2OD1yLkCzNlE4KM7:TR?=	M2HqV3NCVkeHUh?=
LB831-BLC	M2m1d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVLHU3o2UUN3ME2wMlA{OjF7IN88US=>	MXLTRW5ITVJ?
SK-UT-1	Mo\ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3O2SGlEPTB;MD6wN\|IzOSEQvF2=	MYPTRW5ITVJ?
NCI-H1734	M17tWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYHFNpp4UUN3ME2wMlA{OjNizszN	MVHTRW5ITVJ?
OVCAR-8	NVTWSXlCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M133SGlEPTB;MD6wN\|I5OSEQvF2=	MWDTRW5ITVJ?
NCI-H2087	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M373VWlEPTB;MD6wN\|I5QSEQvF2=	MoXnV2FPT0WU
U-87-MG	NVzqenh7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYLJR\|UxRTBwMEOyPUDPxE1?	NUS3cIxxW0GQR1XS
BC-1	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnnVTWM2OD1yLkCzN\|Y4KM7:TR?=	M1LlVnNCVkeHUh?=
ES7	NFnj[G5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{TyT2lEPTB;MD6wN\|M4PCEQvF2=	NWjqOIJRW0GQR1XS
Daudi	MkDhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NW\rR4tsUUN3ME2wMlA{Ozd4IN88US=>	Mnn1V2FPT0WU
RS4-11	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlPpTWM2OD1yLkCzN\|g{KM7:TR?=	MmqxV2FPT0WU
JiyoyeP-2003	NVfvcGxiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2S4WmlEPTB;MD6wN\|M5QCEQvF2=	NV[zR2RuW0GQR1XS
BL-70	NFvJcoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkfGTWM2OD1yLkCzN\|g6KM7:TR?=	NFHhSGVUSU6JRWK=
OS-RC-2	M1HnSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWDJR\|UxRTBwMEOzPVYh\|ryP	NILvOFBUSU6JRWK=
SF268	MoL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVjJR\|UxRTBwMEO0NFEh\|ryP	MlviV2FPT0WU
BV-173	NV7kbHFET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnrNTWM2OD1yLkCzOFI3KM7:TR?=	M2raO3NCVkeHUh?=
DMS-273	MoDOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUPJR\|UxRTBwMEO0O\|kh\|ryP	NYL6W2xXW0GQR1XS
22RV1	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVrwXoJ2UUN3ME2wMlA{PTB5IN88US=>	M3e5ZXNCVkeHUh?=
ES8	NEjpOWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV\4[WF{UUN3ME2wMlA{PTN6IN88US=>	MVnTRW5ITVJ?
KYSE-150	NIf5WHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXP5SFlDUUN3ME2wMlA{PjB6IN88US=>	Mo\OV2FPT0WU
HCC1569	NUHE[mRbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXOxXZk5UUN3ME2wMlA{PjB6IN88US=>	NWPleWp1W0GQR1XS
NB5	M2fIR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlroTWM2OD1yLkCzOlE{KM7:TR?=	NV;POXBUW0GQR1XS
G-402	MlHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlHRTWM2OD1yLkCzOlE1KM7:TR?=	NFG2ZlFUSU6JRWK=
NCI-H1693	NULzVlcyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYrJR\|UxRTBwMEO2NVch\|ryP	MYrTRW5ITVJ?
LB2241-RCC	NInHTlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGjRdmhKSzVyPUCuNFM3PDJizszN	NH7JZXBUSU6JRWK=
KP-4	M3X6V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIHWN21KSzVyPUCuNFM3PjNizszN	M1TKWHNCVkeHUh?=
ML-2	M3;Ce2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUfJR\|UxRTBwMEO2O\|Eh\|ryP	NHPWZ\|VUSU6JRWK=
KU812	NGPLPZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1LwfGlEPTB;MD6wN\|Y5PCEQvF2=	M4[5SXNCVkeHUh?=
LS-411N	M1ryU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIK2V4dKSzVyPUCuNFM4OzFizszN	MmjxV2FPT0WU
OAW-42	M{TSOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NULKZ4VDUUN3ME2wMlA{PzR5IN88US=>	M3zEUXNCVkeHUh?=
HCC38	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoeyTWM2OD1yLkCzO\|cyKM7:TR?=	NXrDTZdNW0GQR1XS
Ca-Ski	NVzGVo9UT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVHJR\|UxRTBwMEO3PFQh\|ryP	MkTvV2FPT0WU
Calu-3	NU\6Z5dmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3GxdmlEPTB;MD6wN\|c5QSEQvF2=	MWnTRW5ITVJ?
KYSE-70	M{CyV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWfJR\|UxRTBwMEO4NVIh\|ryP	M1zRU3NCVkeHUh?=
D-392MG	Ml\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX3JR\|UxRTBwMEO4OFIh\|ryP	MXnTRW5ITVJ?
OVCAR-4	M4j3e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHj2NHRKSzVyPUCuNFM5PThizszN	MVzTRW5ITVJ?
Detroit562	Ml71S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml\xTWM2OD1yLkCzPFczKM7:TR?=	MmLiV2FPT0WU
HEL	NVPXVm1WT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlvoTWM2OD1yLkCzPFkyKM7:TR?=	MkHYV2FPT0WU
MONO-MAC-6	MkTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYHJR\|UxRTBwMEO4PVMh\|ryP	NFnZT4VUSU6JRWK=
LoVo	MnOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXToS5pZUUN3ME2wMlA{QTN\|IN88US=>	M4fQVnNCVkeHUh?=
U-2-OS	NUXWPJltT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmTwTWM2OD1yLkCzPVM2KM7:TR?=	NIXPU4RUSU6JRWK=
A172	NIrTc2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2XZcWlEPTB;MD6wN\|k2KM7:TR?=	M4\Pb3NCVkeHUh?=
OCUB-M	M1O2NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIqzXXZKSzVyPUCuNFM6PjFizszN	M3LD[3NCVkeHUh?=
SW48	M3:0Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWTJR\|UxRTBwMESwN\|Eh\|ryP	NHzTOpVUSU6JRWK=
HC-1	M2nORmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3m5NGlEPTB;MD6wOFA3QSEQvF2=	NHvKdHRUSU6JRWK=
KOSC-2	NVjwdYJQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M333bmlEPTB;MD6wOFEyKM7:TR?=	M122U3NCVkeHUh?=
HDLM-2	NXrSe3NHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWTJR\|UxRTBwMESxNVQh\|ryP	MWLTRW5ITVJ?
CTV-1	NF\pTY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYL5fGllUUN3ME2wMlA1OTF4IN88US=>	MXzTRW5ITVJ?
SH-4	MlexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWXJR\|UxRTBwMESxOFEh\|ryP	M1TLRnNCVkeHUh?=
SW756	M37zZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1vnR2lEPTB;MD6wOFE2PyEQvF2=	M4jk[3NCVkeHUh?=
GCT	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnmyTWM2OD1yLkC0NVYyKM7:TR?=	MUDTRW5ITVJ?
CHL-1	NX3qOoZjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmrETWM2OD1yLkC0NVY6KM7:TR?=	MV\TRW5ITVJ?
LAMA-84	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4jOWGlEPTB;MD6wOFE4OSEQvF2=	NWLNRo1CW0GQR1XS
LS-1034	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlPUTWM2OD1yLkC0NVkyKM7:TR?=	MX;TRW5ITVJ?
NCI-H358	MmHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYLyPWZNUUN3ME2wMlA1OjF{IN88US=>	MUjTRW5ITVJ?
NB13	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVLJR\|UxRTBwMESyNlch\|ryP	M2TDZ3NCVkeHUh?=
TE-9	NHXBO2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnjMTWM2OD1yLkC0NlM4KM7:TR?=	MnH4V2FPT0WU
OE33	NEXrVFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M17oT2lEPTB;MD6wOFI1OSEQvF2=	MYTTRW5ITVJ?
CAL-120	NV\JPVNVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{jreWlEPTB;MD6wOFI1OSEQvF2=	M{m2R3NCVkeHUh?=
DJM-1	MoO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3ryOWlEPTB;MD6wOFI4OiEQvF2=	MmDFV2FPT0WU
SK-MEL-24	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUfYPJkyUUN3ME2wMlA1Ojh\|IN88US=>	NGfnPFZUSU6JRWK=
VA-ES-BJ	NILaS2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkHPTWM2OD1yLkC0NlkzKM7:TR?=	M3P4WXNCVkeHUh?=
MMAC-SF	NVHmOotET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV;ZN\|ZEUUN3ME2wMlA1Ojl5IN88US=>	NV\SbGF5W0GQR1XS
MZ7-mel	MlLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHPPZW5KSzVyPUCuNFQ{OyEQvF2=	MkjVV2FPT0WU
BxPC-3	NXO0coFyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYDJR\|UxRTBwMESzOFEh\|ryP	NH3mVVhUSU6JRWK=
HT-29	Mnn5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3nhZmlEPTB;MD6wOFM2PyEQvF2=	MW\TRW5ITVJ?
SK-MEL-30	NWDxZVNST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH7vPXdKSzVyPUCuNFQ{PjJizszN	NVq2NodbW0GQR1XS
CAL-33	MmnjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUjJR\|UxRTBwMESzO\|Uh\|ryP	MYXTRW5ITVJ?
COLO-680N	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1z2cGlEPTB;MD6wOFQxPyEQvF2=	MXvTRW5ITVJ?
NH-12	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3z4ZWlEPTB;MD6wOFQ1KM7:TR?=	NFPDbXJUSU6JRWK=
HCC1937	M1PKVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmD1TWM2OD1yLkC0OFU3KM7:TR?=	NWHiXG0zW0GQR1XS
IMR-5	NE\oUY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3nsOmlEPTB;MD6wOFQ6KM7:TR?=	NFHpN3BUSU6JRWK=
MC-CAR	Mke3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYDJR\|UxRTBwMES1Olkh\|ryP	M17CRnNCVkeHUh?=
NCI-H747	M3HxPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1iwWmlEPTB;MD6wOFU4KM7:TR?=	Mn7PV2FPT0WU
NCI-H1792	NXv3Xm5IT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkfrTWM2OD1yLkC0OVgyKM7:TR?=	MkDKV2FPT0WU
SW13	M{n3W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF21SnBKSzVyPUCuNFQ2QSEQvF2=	MmTBV2FPT0WU
MLMA	NXfQNYo{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV;0eGU4UUN3ME2wMlA1PjB7IN88US=>	M33tXXNCVkeHUh?=
U251	M3f6fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn64TWM2OD1yLkC0O\|Y{KM7:TR?=	NFq5NVhUSU6JRWK=
U031	NF7nNFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mnq1TWM2OD1yLkC0O\|cyKM7:TR?=	MXrTRW5ITVJ?
ME-180	Mk\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV3JR\|UxRTBwMES3PFIh\|ryP	MlnBV2FPT0WU
SK-MEL-3	NHG1NY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX\pd2k2UUN3ME2wMlA1QDB{IN88US=>	NIXP[3RUSU6JRWK=
MOLT-4	Mn7GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVXJR\|UxRTBwMES4NFMh\|ryP	M{e1OnNCVkeHUh?=
PF-382	NF7r[GFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mk\5TWM2OD1yLkC0PFI3KM7:TR?=	NH2zRYlUSU6JRWK=
NUGC-3	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYfJR\|UxRTBwMES4Nlch\|ryP	NHPETFdUSU6JRWK=
NCI-H1417	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2\FS2lEPTB;MD6wOFg6KM7:TR?=	MU\TRW5ITVJ?
COLO-205	M33KN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH;2boNKSzVyPUCuNFQ6OTlizszN	NITJRnZUSU6JRWK=
TE-441-T	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUnJR\|UxRTBwMES5N{DPxE1?	MUnTRW5ITVJ?
MKN1	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MojOTWM2OD1yLkC0PVMh\|ryP	Ml6wV2FPT0WU
UM-UC-3	MnPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mk[4TWM2OD1yLkC0PVUh\|ryP	MX3TRW5ITVJ?
SF126	NFXON3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV7zc\|FUUUN3ME2wMlA2ODFizszN	MYrTRW5ITVJ?
LB1047-RCC	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{O3fGlEPTB;MD6wOVA{OSEQvF2=	NFOyVY1USU6JRWK=
A253	NWDObHl7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXTJR\|UxRTBwMEWwOVIh\|ryP	Mn\6V2FPT0WU
NCI-H1963	M13rdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWDXTZVTUUN3ME2wMlA2OTd4IN88US=>	MUnTRW5ITVJ?
VM-CUB-1	NH;EVVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4XIbGlEPTB;MD6wOVMyOSEQvF2=	NIrKSHhUSU6JRWK=
T-24	NHTEPYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHuzb2xKSzVyPUCuNFU{QDRizszN	MUDTRW5ITVJ?
K-562	NG[3VWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH70[I1KSzVyPUCuNFU{QDdizszN	NWHYToZxW0GQR1XS
ARH-77	Mnv3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1\HSGlEPTB;MD6wOVM6PSEQvF2=	NH[wNZJUSU6JRWK=
CA46	NHn5ZYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV;tboRHUUN3ME2wMlA2PDNizszN	NH3nTJVUSU6JRWK=
HCC70	NVHKW4RVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2G5WWlEPTB;MD6wOVQ2OiEQvF2=	M4DTWnNCVkeHUh?=
ST486	NIHrRZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4DreWlEPTB;MD6wOVUzPSEQvF2=	MoW2V2FPT0WU
COLO-741	NIC0V4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX7JR\|UxRTBwMEW1N\|Eh\|ryP	NYrpXZNEW0GQR1XS
SK-PN-DW	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1LLWmlEPTB;MD6wOVU5QCEQvF2=	MXzTRW5ITVJ?
BL-41	M2HoZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYTJR\|UxRTBwMEW1PVYh\|ryP	NVe1dGJPW0GQR1XS
D-263MG	Mn\qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1;lWWlEPTB;MD6wOVY5OyEQvF2=	NEPWeVJUSU6JRWK=
KE-37	MnTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1nS[2lEPTB;MD6wOVY5OyEQvF2=	M4rVOHNCVkeHUh?=
LU-134-A	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGjSNYtKSzVyPUCuNFU4OTVizszN	MofNV2FPT0WU
HCC2157	NHf1UGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MofrTWM2OD1yLkC1O\|M{KM7:TR?=	MojCV2FPT0WU
GAK	M4D5WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFPhSY9KSzVyPUCuNFU4OzRizszN	M17pZ3NCVkeHUh?=
IST-SL2	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXrGTIxqUUN3ME2wMlA2PzR\|IN88US=>	MVnTRW5ITVJ?
KMOE-2	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEfHOIJKSzVyPUCuNFU4PDlizszN	NUXv[5h[W0GQR1XS
SW1573	M3TzVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3zlb2lEPTB;MD6wOVgxOiEQvF2=	NYDu[5FQW0GQR1XS
SCC-9	M3jBOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlK0TWM2OD1yLkC1PFch\|ryP	MlLKV2FPT0WU
MDA-MB-361	NETaSVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2m2eGlEPTB;MD6wOVg4OiEQvF2=	M2qxUHNCVkeHUh?=
BHT-101	NU\mbGlPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVXJR\|UxRTBwMEW4O\|Yh\|ryP	NIrVbpZUSU6JRWK=
NCI-H1770	NX7XdoNyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4G0O2lEPTB;MD6wOVg4QSEQvF2=	MkfZV2FPT0WU
UACC-893	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYXmNHhCUUN3ME2wMlA2QDl4IN88US=>	MVPTRW5ITVJ?
NCI-H226	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWLKUHdbUUN3ME2wMlA2QTh6IN88US=>	MV7TRW5ITVJ?
HLE	NUXjb4RWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mmn4TWM2OD1yLkC2NFgzKM7:TR?=	MnzwV2FPT0WU
NCI-H1703	NEPzcVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmC4TWM2OD1yLkC2NVc5KM7:TR?=	MlzTV2FPT0WU
KURAMOCHI	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXTJR\|UxRTBwME[xPFkh\|ryP	NV\XS4VoW0GQR1XS
RH-1	M3ziR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mli2TWM2OD1yLkC2NlMh\|ryP	MWPTRW5ITVJ?
DSH1	NY\lN3JnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2HpTWlEPTB;MD6wOlI4KM7:TR?=	NEDINmtUSU6JRWK=
CAMA-1	M2TSOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Moe5TWM2OD1yLkC2N\|A{KM7:TR?=	M4i1THNCVkeHUh?=
NCI-H1437	MmXnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHH2[XRKSzVyPUCuNFY{OjhizszN	M3TpOHNCVkeHUh?=
HuP-T4	M{TVfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFjtRoRKSzVyPUCuNFY2QDZizszN	NFTCOopUSU6JRWK=
HCT-15	Mor4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXT5e2lVUUN3ME2wMlA3PTl5IN88US=>	NX;iWlVYW0GQR1XS
NCCIT	MlvBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml\yTWM2OD1yLkC2OlA1KM7:TR?=	MknzV2FPT0WU
BOKU	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUDJR\|UxRTBwME[2O\|Qh\|ryP	M{P3W3NCVkeHUh?=
FADU	MnrIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWnJR\|UxRTBwME[3OFUh\|ryP	MVvTRW5ITVJ?
SUP-T1	NGXK[ZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVrVS4NMUUN3ME2wMlA3PzZizszN	MXPTRW5ITVJ?
L-363	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3H3[WlEPTB;MD6wOlkxOSEQvF2=	NFnNXpZUSU6JRWK=
KNS-81-FD	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXXpbFN[UUN3ME2wMlA3QTF6IN88US=>	NGi5PYVUSU6JRWK=
SU-DHL-1	NYOzUWY2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4Du[WlEPTB;MD6wOlkzKM7:TR?=	M4joR3NCVkeHUh?=
HuH-7	NHPYd4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFXROZBKSzVyPUCuNFcxOzVizszN	NF\TVoJUSU6JRWK=
BT-474	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX\JR\|UxRTBwMEewOlEh\|ryP	M363W3NCVkeHUh?=
CAPAN-1	MlrnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2C5fWlEPTB;MD6wO\|E1OyEQvF2=	MXTTRW5ITVJ?
HEC-1	MljsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX75U3g1UUN3ME2wMlA4OTZzIN88US=>	NH;TT\|VUSU6JRWK=
NOMO-1	M1LtOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXjicI5rUUN3ME2wMlA4OTd{IN88US=>	MWfTRW5ITVJ?
KM-H2	NHT0N41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NInueWRKSzVyPUCuNFczPDFizszN	M{PGbnNCVkeHUh?=
EB2	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1joNGlEPTB;MD6wO\|I5PSEQvF2=	NUXDN3ZRW0GQR1XS
LU-99A	Ml7QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGjmXHdKSzVyPUCuNFczQDdizszN	MYHTRW5ITVJ?
WSU-NHL	MmfxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVvJR\|UxRTBwMEezNlkh\|ryP	MoXnV2FPT0WU
Calu-1	NFHJbllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYnpZlJMUUN3ME2wMlA4OzN{IN88US=>	M3zQRnNCVkeHUh?=
U-698-M	NWi1TG82T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnzlTWM2OD1yLkC3N\|gzKM7:TR?=	MU\TRW5ITVJ?
T98G	NW\wSY1IT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkG4TWM2OD1yLkC3OFIyKM7:TR?=	M3HCfHNCVkeHUh?=
GI-ME-N	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV;wfnJWUUN3ME2wMlA4PDJ4IN88US=>	NELHdIxUSU6JRWK=
LS-513	NHH4SVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVK2NI5IUUN3ME2wMlA4PDV4IN88US=>	NFzsWmJUSU6JRWK=
UACC-257	NWnvUZZyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1jie2lEPTB;MD6wO\|UxPSEQvF2=	MV7TRW5ITVJ?
DK-MG	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVjJR\|UxRTBwMEe1NlYh\|ryP	M2T0VXNCVkeHUh?=
EW-11	MlfxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHvkc3FKSzVyPUCuNFc2OzVizszN	NEjpbYFUSU6JRWK=
CHP-126	NWC0[XZkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnrzTWM2OD1yLkC3OVY2KM7:TR?=	NV3Wc\|A4W0GQR1XS
Saos-2	NWrKSpZsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1O3PWlEPTB;MD6wO\|U6PyEQvF2=	MkDTV2FPT0WU
Ramos-2G6-4C10	NHPBUVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{exZmlEPTB;MD6wO\|Y1QCEQvF2=	NFzhTYpUSU6JRWK=
L-428	Mn;IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF\Y[ZVKSzVyPUCuNFc4ODRizszN	MoLKV2FPT0WU
HOP-92	NXPCR4RoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWHJR\|UxRTBwMEe3NVEh\|ryP	MoDCV2FPT0WU
PANC-08-13	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NILXRWFKSzVyPUCuNFc4OTZizszN	M2nqUnNCVkeHUh?=
TUR	M3fBd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4DoXmlEPTB;MD6wO\|c{OyEQvF2=	NWjJPYJsW0GQR1XS
DMS-153	NFvsPZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGja[HRKSzVyPUCuNFc4OzVizszN	MmrxV2FPT0WU
NCI-N87	Mn3hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1fGTGlEPTB;MD6wO\|c6QSEQvF2=	MUHTRW5ITVJ?
ESS-1	NIXT[2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYTJR\|UxRTBwMEe4Olgh\|ryP	MYfTRW5ITVJ?
CP66-MEL	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFjhVG5KSzVyPUCuNFc5QDdizszN	NFzLbIlUSU6JRWK=
NCI-SNU-1	NIDoXnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWHJR\|UxRTBwMEe4PFgh\|ryP	MULTRW5ITVJ?
Calu-6	Mkm5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnjFTWM2OD1yLkC3PVY2KM7:TR?=	NGfnWIVUSU6JRWK=
COLO-668	MlPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnqxTWM2OD1yLkC3PVg1KM7:TR?=	MUXTRW5ITVJ?
SK-CO-1	MoXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUnJR\|UxRTBwMEe5PVIh\|ryP	MmHUV2FPT0WU
NCI-H2347	M3fpZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUTMVnpZUUN3ME2wMlA5ODJ6IN88US=>	M4e2[3NCVkeHUh?=
CAL-27	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NI\zfHdKSzVyPUCuNFgyPTZizszN	MWLTRW5ITVJ?
COLO-684	M1:2dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWLJOI8zUUN3ME2wMlA5OTV6IN88US=>	MYjTRW5ITVJ?
LNCaP-Clone-FGC	Ml3pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWTJR\|UxRTBwMEixOlUh\|ryP	MWfTRW5ITVJ?
NCI-H1304	MnHsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF;3Vm1KSzVyPUCuNFgzPzFizszN	MnH2V2FPT0WU
KP-N-YS	NFrzdGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWLJR\|UxRTBwMEizOFUh\|ryP	NGm2WpdUSU6JRWK=
CP50-MEL-B	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1vmdGlEPTB;MD6wPFM3QCEQvF2=	Mlv6V2FPT0WU
LAN-6	MkTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoLaTWM2OD1yLkC4OFk5KM7:TR?=	MVfTRW5ITVJ?
ABC-1	NX\s[ZlOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV\CXmpUUUN3ME2wMlA5PzV7IN88US=>	M4jmPHNCVkeHUh?=
ES3	NE\nZ\|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NW\JSGp3UUN3ME2wMlA5PzZ\|IN88US=>	NV;xTnNJW0GQR1XS
COLO-792	NFXz[3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEfsW5RKSzVyPUCuNFg5PTVizszN	MVnTRW5ITVJ?
J-RT3-T3-5	Mn7WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2TpZWlEPTB;MD6wPFk3QCEQvF2=	MYnTRW5ITVJ?
EFO-21	M1rUd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHfjPVZKSzVyPUCuNFg6QTFizszN	NYn1UlFqW0GQR1XS
MDA-MB-231	NVrHSIVIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIK1U3NKSzVyPUCuNFkxQDJizszN	MYLTRW5ITVJ?
SBC-5	MnW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUi0RotuUUN3ME2wMlA6OTl\|IN88US=>	MlToV2FPT0WU
SAS	NXLNPGt5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mnv2TWM2OD1yLkC5NlE2KM7:TR?=	M4jCfnNCVkeHUh?=
SNU-387	M1Tlbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWDDXVNRUUN3ME2wMlA6OjF6IN88US=>	NXnhRWdnW0GQR1XS
EVSA-T	M2Ozemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWfvWpNTUUN3ME2wMlA6OjZ3IN88US=>	Mn6wV2FPT0WU
MHH-PREB-1	NVfxb24zT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml3DTWM2OD1yLkC5N\|Eh\|ryP	NWnRSGM{W0GQR1XS
KARPAS-45	M4fhbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{LyUGlEPTB;MD6wPVM1PSEQvF2=	M3rY[HNCVkeHUh?=
SJRH30	MlnXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHGxO5FKSzVyPUCuNFk1PDRizszN	M2XVVXNCVkeHUh?=
JEG-3	NWO0SVl[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3TCRmlEPTB;MD6wPVUxPSEQvF2=	MYjTRW5ITVJ?
NB12	NVrIdFVJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVHJRXJrUUN3ME2wMlA6PTF6IN88US=>	NEXCbJBUSU6JRWK=
HCC1419	NE[xOVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUDJR\|UxRTBwMEm1OFEh\|ryP	M4ezb3NCVkeHUh?=
HCC1599	M4HTfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MojKTWM2OD1yLkC5OlAyKM7:TR?=	NHPibHRUSU6JRWK=
IPC-298	MnL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3zMVWlEPTB;MD6wPVY1PCEQvF2=	MlywV2FPT0WU
MPP-89	Mn71S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkLPTWM2OD1yLkC5O\|IyKM7:TR?=	MoPJV2FPT0WU
HT-1376	NHz2fHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1m2eGlEPTB;MD6wPVg3OSEQvF2=	M13jenNCVkeHUh?=
MDA-MB-468	NFjXdW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnjzTWM2OD1yLkC5PVg2KM7:TR?=	NULrWGQ6W0GQR1XS
HCC2218	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHj0b2xKSzVyPUCuNFk6QTlizszN	Mne4V2FPT0WU
LK-2	M4XBemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUPGUoxyUUN3ME2wMlExOTd4IN88US=>	MVvTRW5ITVJ?
GR-ST	NF\l[FRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1LWT2lEPTB;MD6xNFIyKM7:TR?=	M1vMb3NCVkeHUh?=
PFSK-1	NHjaU4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkK1TWM2OD1yLkGwNlY4KM7:TR?=	M4XzXHNCVkeHUh?=
NCI-H2052	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIfERndKSzVyPUCuNVA1ODdizszN	NW\P[3lxW0GQR1XS
A673	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NY\Y[lc1UUN3ME2wMlExPDNzIN88US=>	M2O2S3NCVkeHUh?=
EKVX	MlvxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MofITWM2OD1yLkGwOFg{KM7:TR?=	MXzTRW5ITVJ?
23132-87	MlLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVzJR\|UxRTBwMUC0PFgh\|ryP	MV\TRW5ITVJ?
EW-18	MmniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX;JR\|UxRTBwMUC2NFQh\|ryP	M1vXSnNCVkeHUh?=
KU-19-19	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlvGTWM2OD1yLkGwPFE4KM7:TR?=	NYnxXY9VW0GQR1XS
NCI-H441	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWXJR\|UxRTBwMUC4PVkh\|ryP	NFPXWodUSU6JRWK=
COLO-824	MoKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NELWcVJKSzVyPUCuNVExOiEQvF2=	M3\VcHNCVkeHUh?=
HCC1806	NFnlNWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV;JR\|UxRTBwMUGxNFgh\|ryP	M3exbHNCVkeHUh?=
SK-MM-2	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXrxWFNZUUN3ME2wMlEyOTR3IN88US=>	NGHnTppUSU6JRWK=
DEL	Mn[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4m3bWlEPTB;MD6xNVE6OiEQvF2=	MYHTRW5ITVJ?
NCI-H661	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVnHZYNZUUN3ME2wMlEyOTl3IN88US=>	MmHkV2FPT0WU
LC4-1	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUXDVFhbUUN3ME2wMlEyPDZ4IN88US=>	MYTTRW5ITVJ?
BEN	NH:5dG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{DUfmlEPTB;MD6xNVYxPyEQvF2=	M{C1eHNCVkeHUh?=
RPMI-8226	NH;UNmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX3JR\|UxRTBwMUG3NVkh\|ryP	NWqyO\|ZvW0GQR1XS
AU565	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn\VTWM2OD1yLkGxPFMyKM7:TR?=	NXTMcVFTW0GQR1XS
CAS-1	NI\ER4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NI[yNZdKSzVyPUCuNVE6PjRizszN	MmTpV2FPT0WU
UACC-62	NGjwPYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX;SNWRYUUN3ME2wMlEzOTJizszN	NF\mW5hUSU6JRWK=
C-4-II	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{PpW2lEPTB;MD6xNlE4KM7:TR?=	NW\uXpQ{W0GQR1XS
DMS-53	NVfnXWZVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVnJR\|UxRTBwMUKyO\|Yh\|ryP	NGLnfFdUSU6JRWK=
SK-MEL-2	M3;XWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoTwTWM2OD1yLkGyOFYh\|ryP	MYHTRW5ITVJ?
S-117	NI\CXHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUHJR\|UxRTBwMUK2O\|Qh\|ryP	NHPEfm5USU6JRWK=
ChaGo-K-1	NH\XR2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEXPXnRKSzVyPUCuNVI3QTlizszN	MU\TRW5ITVJ?
KMS-12-PE	NY[2WJk6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV3hb21KUUN3ME2wMlEzQDZ7IN88US=>	NIS3fI1USU6JRWK=
PC-3	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEHYbWxKSzVyPUCuNVMyPzdizszN	NWW1XHNWW0GQR1XS
RERF-LC-MS	MkXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX\JR\|UxRTBwMUO0N{DPxE1?	M2[wfHNCVkeHUh?=
GMS-10	NFXFT3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVr5[GhrUUN3ME2wMlE{PDR2IN88US=>	MnLkV2FPT0WU
CTB-1	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3nBcmlEPTB;MD6xN\|Q3QSEQvF2=	NH;KVZFUSU6JRWK=
SCC-25	NXrPVWR5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVrIRY9TUUN3ME2wMlE{PTh6IN88US=>	M3zTUXNCVkeHUh?=
NCI-H1755	M2TWTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXy5cXNzUUN3ME2wMlE{QDJ5IN88US=>	NWjmV4w5W0GQR1XS
D-542MG	NIXIOYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2TLTmlEPTB;MD6xN\|k3PSEQvF2=	M{j0ZXNCVkeHUh?=
KARPAS-422	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3zq[2lEPTB;MD6xOFA{PyEQvF2=	NFH3UGVUSU6JRWK=
OVCAR-3	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYHJR\|UxRTBwMUSwO\|gh\|ryP	MYXTRW5ITVJ?
NCI-H1092	MlXTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml;aTWM2OD1yLkG0NVAyKM7:TR?=	NELPVGtUSU6JRWK=
HH	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH\NdlhKSzVyPUCuNVQzODFizszN	M2LEXHNCVkeHUh?=
NB1	M3zNcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2LseWlEPTB;MD6xOFQzPiEQvF2=	MUDTRW5ITVJ?
HD-MY-Z	NEi0[45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2LuSGlEPTB;MD6xOFQzQSEQvF2=	M1TCTXNCVkeHUh?=
SHP-77	Mn3tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEHBeFdKSzVyPUCuNVQ1PzJizszN	M1nrRnNCVkeHUh?=
U-266	Mn7YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYf5T3JmUUN3ME2wMlE1PDhizszN	MX\TRW5ITVJ?
GI-1	M2DvUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEH4RlRKSzVyPUCuNVQ4PzJizszN	MWjTRW5ITVJ?
NCI-H1522	NIT3cJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mof0TWM2OD1yLkG0O\|g4KM7:TR?=	M3\hPXNCVkeHUh?=
647-V	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUjpc5M2UUN3ME2wMlE1QTR{IN88US=>	M3HETXNCVkeHUh?=
HCT-116	NUOwWmVCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIn5O4RKSzVyPUCuNVUyPjlizszN	MYHTRW5ITVJ?
NCI-H2081	MoPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF3ORVlKSzVyPUCuNVUzOThizszN	M{nQdnNCVkeHUh?=
THP-1	NX;2R3J{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGTlZZRKSzVyPUCuNVU{OzNizszN	NHjacIdUSU6JRWK=
LU-165	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH3NNXNKSzVyPUCuNVU1OTNizszN	NYjjW3RzW0GQR1XS
RCM-1	NUDuUWdwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3nkNGlEPTB;MD6xOVY5KM7:TR?=	M4LBVHNCVkeHUh?=
COR-L279	NF3NWHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEXmdIZKSzVyPUCuNVU5OzZizszN	MXLTRW5ITVJ?
SK-NEP-1	NWPIXWt7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFHGS3ZKSzVyPUCuNVU5QTlizszN	M3G0UnNCVkeHUh?=
KLE	MkPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX7rOFZPUUN3ME2wMlE3OTZ7IN88US=>	M1\hZXNCVkeHUh?=
NCI-H2170	MoTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEW0W4dKSzVyPUCuNVY{ODRizszN	MWLTRW5ITVJ?
TGW	NEnzPY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnLsTWM2OD1yLkG2OFcyKM7:TR?=	MlfpV2FPT0WU
CAL-72	MnPYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFvmc5JKSzVyPUCuNVY2QSEQvF2=	NYDNU5JnW0GQR1XS
K052	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX;JR\|UxRTBwMUewOlEh\|ryP	M1zCdXNCVkeHUh?=
COR-L88	NXnWPYJQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmLDTWM2OD1yLkG3NVE1KM7:TR?=	M1fLOnNCVkeHUh?=
HSC-4	NFLOblFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnqyTWM2OD1yLkG3NVYh\|ryP	MlnYV2FPT0WU
GOTO	NXe1dHhIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1HXfmlEPTB;MD6xO\|I1PiEQvF2=	MoToV2FPT0WU
MEG-01	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYjJR\|UxRTBwMUeyOVch\|ryP	NVXpOnZ3W0GQR1XS
MDA-MB-134-VI	MlLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoDZTWM2OD1yLkG3N\|Y4KM7:TR?=	MV7TRW5ITVJ?
NCI-H596	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVnJR\|UxRTBwMUezPEDPxE1?	NVLHeHRKW0GQR1XS
EW-3	Mn7PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVjPTVVkUUN3ME2wMlE4PDh4IN88US=>	NXjLb\|hkW0GQR1XS
NCI-H1573	NIGxXG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml7STWM2OD1yLkG3Olc5KM7:TR?=	Mn21V2FPT0WU
SKG-IIIa	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXrJR\|UxRTBwMUe4NFch\|ryP	NIDWVVJUSU6JRWK=
SK-N-DZ	NUnSS3BrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFTUXIJKSzVyPUCuNVc5QDNizszN	MorpV2FPT0WU
EGI-1	M4DOeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYLJR\|UxRTBwMUe5O{DPxE1?	NV;Ebod6W0GQR1XS
COLO-320-HSR	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVTaNXJIUUN3ME2wMlE5PDl\|IN88US=>	MWPTRW5ITVJ?
DOHH-2	M{LaXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3nMWmlEPTB;MD6xPFU3QSEQvF2=	NXTOTVhSW0GQR1XS
MS-1	NHnySlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUH4bIE6UUN3ME2wMlE5PiEQvF2=	MXfTRW5ITVJ?
NCI-H2171	NEnJW29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX[wcGZbUUN3ME2wMlE5PjR7IN88US=>	NF7KN\|FUSU6JRWK=
NCI-H526	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF;ZTnRKSzVyPUCuNVg3QTZizszN	NUDnW2c4W0GQR1XS
MDA-MB-415	NV6zfVUxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mk\VTWM2OD1yLkG5O\|Q5KM7:TR?=	NFvXVndUSU6JRWK=
ECC4	MmHWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1HESmlEPTB;MD6xPVg3OyEQvF2=	MWTTRW5ITVJ?
C2BBe1	NXHrR2Y4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWDXW5loUUN3ME2wMlE6QDl\|IN88US=>	MXXTRW5ITVJ?
TE-11	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWiwTlQzUUN3ME2wMlE6QTd3IN88US=>	M2S5OXNCVkeHUh?=
LU-65	MkjTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mnn6TWM2OD1yLkKwNlEyKM7:TR?=	MkPJV2FPT0WU
MKN45	M1rOXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV73UoJ5UUN3ME2wMlIxPjRizszN	M{fLTHNCVkeHUh?=
TGBC1TKB	M2H0N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWXiVWhjUUN3ME2wMlIxQTl5IN88US=>	MknnV2FPT0WU
NCI-H2196	MmD6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVXJR\|UxRTBwMkG3OFch\|ryP	NE\3fJJUSU6JRWK=
M14	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEHnbmVKSzVyPUCuNlE5ODNizszN	NVvlR5pzW0GQR1XS
NCI-H1436	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIDlcmJKSzVyPUCuNlE5OjZizszN	NGfjfopUSU6JRWK=
EB-3	NIO4dVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUfmU\|hOUUN3ME2wMlIzOzd4IN88US=>	MnfoV2FPT0WU
HT	MkDFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYjXdJBTUUN3ME2wMlIzPTZ4IN88US=>	NHznRYlUSU6JRWK=
A3-KAW	M4[1cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2L3[2lEPTB;MD6yNlcxQCEQvF2=	MXXTRW5ITVJ?
DB	M2\VWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVvr[GFOUUN3ME2wMlIzQDZ3IN88US=>	NInnZWhUSU6JRWK=
KARPAS-299	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3j0R2lEPTB;MD6yNlk6PCEQvF2=	M{jxT3NCVkeHUh?=
IM-9	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXPa[GRoUUN3ME2wMlI{PDd4IN88US=>	MVnTRW5ITVJ?
NCI-H838	M33ZPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYDJR\|UxRTBwMkO3NVQh\|ryP	NEnkU5pUSU6JRWK=
NB10	M2L1emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2q0TWlEPTB;MD6yN\|c{OSEQvF2=	NYHCUndXW0GQR1XS
NCI-H2141	MmrLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYL4NHQxUUN3ME2wMlI{QDRzIN88US=>	MYDTRW5ITVJ?
LB647-SCLC	M1S4e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mo\MTWM2OD1yLkK0NFE1KM7:TR?=	NH;CXo1USU6JRWK=
NCI-H23	NULvcldVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NY\tNHdxUUN3ME2wMlI1ODV7IN88US=>	MVjTRW5ITVJ?
MN-60	M4LNSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYrJR\|UxRTBwMkSyN\|kh\|ryP	MUnTRW5ITVJ?
CAL-148	Mm\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NE\IZm1KSzVyPUCuNlQzQDJizszN	MoTGV2FPT0WU
EFE-184	MmLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXrJR\|UxRTBwMkS1PVch\|ryP	NI\OZlNUSU6JRWK=
TE-6	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlzDTWM2OD1yLkK0OlEzKM7:TR?=	MnrnV2FPT0WU
SN12C	NV3CVlRCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYrJR\|UxRTBwMkS2PVQh\|ryP	NGjoVJVUSU6JRWK=
CAKI-1	M1S4Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEOzVGRKSzVyPUCuNlUxQDZizszN	M3nJOXNCVkeHUh?=
MHH-NB-11	M3Tz[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkWzTWM2OD1yLkK1N\|Uh\|ryP	MXLTRW5ITVJ?
DOK	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVXH[m9DUUN3ME2wMlI2QTNizszN	NWH2WHhXW0GQR1XS
Raji	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mlz0TWM2OD1yLkK2OlA{KM7:TR?=	NFjKeVVUSU6JRWK=
OAW-28	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3\1eGlEPTB;MD6yOlY4PyEQvF2=	MYrTRW5ITVJ?
P30-OHK	NF7URY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M16xemlEPTB;MD6yOlkxPSEQvF2=	MnP3V2FPT0WU
NCI-H69	M{LufWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn7lTWM2OD1yLkK3NlAyKM7:TR?=	MWPTRW5ITVJ?
SK-N-AS	NVLzOY5sT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYXJR\|UxRTBwMkeyNkDPxE1?	MoTiV2FPT0WU
BE-13	NF;x[VFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NE\JW3pKSzVyPUCuNlczPDlizszN	MUnTRW5ITVJ?
NCI-H1618	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoTSTWM2OD1yLkK3OVEh\|ryP	M4DSTnNCVkeHUh?=
NCI-SNU-5	MkP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVLLWIdRUUN3ME2wMlI4PjF\|IN88US=>	M3rIVnNCVkeHUh?=
NCI-H1694	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFrJO5BKSzVyPUCuNlc4OzNizszN	MmjCV2FPT0WU
RL	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1jaR2lEPTB;MD6yPFE4PCEQvF2=	M2POPXNCVkeHUh?=
SW684	NYrwboo2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXnJR\|UxRTBwMkizPFMh\|ryP	M2XnT3NCVkeHUh?=
EW-24	NH7NTWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4HscWlEPTB;MD6yPFgyKM7:TR?=	NWXxeYozW0GQR1XS
NCI-H510A	MkHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mlq0TWM2OD1yLkK5N\|A1KM7:TR?=	NUXTdodpW0GQR1XS
Mo-T	Mn23S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIXTfYlKSzVyPUCuNlk{OzFizszN	M3XQV3NCVkeHUh?=
LB373-MEL-D	MoO0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2L5XmlEPTB;MD6yPVQ{OSEQvF2=	NIfXOmpUSU6JRWK=
NCI-H28	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MU\JR\|UxRTBwMkm4N\|ch\|ryP	NYnjVVROW0GQR1XS
NCI-H446	NX;iN2szT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml7jTWM2OD1yLkK5PVIyKM7:TR?=	NYjJcZZXW0GQR1XS
L-540	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUXJR\|UxRTBwM{CwPFkh\|ryP	MnO3V2FPT0WU
MKN7	NXz4fmxGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4T1RWlEPTB;MD6zNFY{QSEQvF2=	MWPTRW5ITVJ?
OPM-2	NFzybVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnvvTWM2OD1yLkOxNFY1KM7:TR?=	NVLPeopnW0GQR1XS
BT-20	MmHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3jzOWlEPTB;MD6zNVA6QSEQvF2=	M3vaVXNCVkeHUh?=
KP-N-YN	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVLCfXdDUUN3ME2wMlMyOTF6IN88US=>	M4TNOXNCVkeHUh?=
MDA-MB-175-VII	MnznS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYPqfWlCUUN3ME2wMlMzOzR6IN88US=>	MnHtV2FPT0WU
EFM-19	Mn:yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXXwV5R4UUN3ME2wMlM{OTN{IN88US=>	MVrTRW5ITVJ?
COLO-678	MlK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkLsTWM2OD1yLkOzN\|g6KM7:TR?=	NUfYXlY2W0GQR1XS
COLO-829	NGL6W3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUPGc2N[UUN3ME2wMlM1PDV{IN88US=>	MmCwV2FPT0WU
A704	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHP4e\|JKSzVyPUCuN\|Q6OjNizszN	MVrTRW5ITVJ?
NCI-H719	NGG2WI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mo\BTWM2OD1yLkO1NVI1KM7:TR?=	NHizZopUSU6JRWK=
MFE-280	NVvzSFR1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NW\TN\|h[UUN3ME2wMlM2PzF3IN88US=>	NEf4c2xUSU6JRWK=
DMS-114	MljFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYrQ[o1xUUN3ME2wMlM3OTJizszN	M{j3OXNCVkeHUh?=
RMG-I	NXiyT\|h6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVvJR\|UxRTBwM{[2PVEh\|ryP	MkS3V2FPT0WU
SK-N-FI	M3ftdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3O0dWlEPTB;MD6zO\|Y{PyEQvF2=	MnTIV2FPT0WU
LB2518-MEL	NX62Wpc5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1LaWmlEPTB;MD60NFg4OiEQvF2=	NWX3WpNZW0GQR1XS
IST-MES1	NUf6V\|ZvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUfwPHZEUUN3ME2wMlQyOSEQvF2=	NECwPIJUSU6JRWK=
HPAF-II	NYTaWI5tT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHjnXmFKSzVyPUCuOFEyOTdizszN	M1XLenNCVkeHUh?=
NCI-H1882	M1jZbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWDpO3RRUUN3ME2wMlQyPzh2IN88US=>	NI\GSo9USU6JRWK=
JVM-2	M3zWemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWPJR\|UxRTBwNES0NFEh\|ryP	MnvWV2FPT0WU
T47D	NUKyPVBbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX3JR\|UxRTBwNES1Nlgh\|ryP	M1rCV3NCVkeHUh?=
MHH-CALL-2	M2TkWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXzJR\|UxRTBwNES4N{DPxE1?	M{\mZnNCVkeHUh?=
NCI-H716	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVTMVpR6UUN3ME2wMlQ1QDR6IN88US=>	MVHTRW5ITVJ?
NEC8	M1fa[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWjJR\|UxRTBwNEWxOFUh\|ryP	MUHTRW5ITVJ?
UACC-812	MnfDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYjJR\|UxRTBwNE[3O\|Yh\|ryP	M4\jfnNCVkeHUh?=
D-502MG	MoT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2n3d2lEPTB;MD60PFA{KM7:TR?=	NH3kc\|RUSU6JRWK=
CaR-1	NXraTZZ3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX6zfYM6UUN3ME2wMlUxOzZ5IN88US=>	NXHNTmt{W0GQR1XS
LU-139	NUfZT3hCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEK0bpNKSzVyPUCuOVE1PTdizszN	Mnv2V2FPT0WU
RPMI-8402	Mn:yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYTJR\|UxRTBwNUKyNFch\|ryP	M2C4Z3NCVkeHUh?=
SW1088	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGWyUmxKSzVyPUCuOVM5PjlizszN	MVrTRW5ITVJ?
JVM-3	M4Czd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUK0fXpXUUN3ME2wMlU1OTF5IN88US=>	M1XmXXNCVkeHUh?=
YAPC	Mnn6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnH4TWM2OD1yLkW1NlEyKM7:TR?=	NHn4SZJUSU6JRWK=
KG-1	NF\Q[W9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlnsTWM2OD1yLkW1PVg1KM7:TR?=	NEn2RW5USU6JRWK=
C32	NGC2bG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1rVS2lEPTB;MD61O\|MyOyEQvF2=	NUD3SIs4W0GQR1XS
IST-SL1	M2fzemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIW2UHJKSzVyPUCuOlA1OzVizszN	MXXTRW5ITVJ?
NCI-H2126	M2e4SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmrrTWM2OD1yLk[zNVUzKM7:TR?=	NYnQeZV6W0GQR1XS
HCC1954	M3uyZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYPJR\|UxRTBwNkS3NlYh\|ryP	MXfTRW5ITVJ?
WM-115	M33tPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2fxbmlEPTB;MD62OVA6OiEQvF2=	NGXUSmRUSU6JRWK=
NB6	NIDQWHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVLJR\|UxRTBwNkezN\|Uh\|ryP	MnixV2FPT0WU
TYK-nu	M1ixT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M33rO2lEPTB;MD62O\|k2OiEQvF2=	NXXXe5NRW0GQR1XS
KY821	NX;3ZndLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEW5OHNKSzVyPUCuO\|AzOjlizszN	NWTISWRJW0GQR1XS
SIMA	NWDUZVdoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYPJR\|UxRTBwN{G3NVkh\|ryP	MV\TRW5ITVJ?
RCC10RGB	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVqySYY4UUN3ME2wMlcyQTF6IN88US=>	NEPNellUSU6JRWK=
LN-405	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2DKNWlEPTB;MD63OFM3KM7:TR?=	NWfhPJpqW0GQR1XS
NCI-H1155	NYXTNZJRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEnvbG5KSzVyPUCuO\|Q5PjhizszN	NWrQ[m9{W0GQR1XS
SCLC-21H	NXrEUXNCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkjnTWM2OD1yLke2PVA{KM7:TR?=	NH3MSHpUSU6JRWK=
DMS-79	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{G0TGlEPTB;MD63O\|g1PSEQvF2=	NYnac2JRW0GQR1XS
EC-GI-10	NWrHZphVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3\ocGlEPTB;MD63O\|k4PSEQvF2=	MV;TRW5ITVJ?
KNS-42	NVfGVnhHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXuzcHRbUUN3ME2wMlc5QDNzIN88US=>	NXvP[lg{W0GQR1XS
SNU-475	M2XWfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWizdXpwUUN3ME2wMlc6OjB{IN88US=>	MlLoV2FPT0WU
SF539	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHLjUFRKSzVyPUCuO\|k6OjVizszN	MnfBV2FPT0WU
SW1417	NHjWSIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFrZSXNKSzVyPUCuPFE{OzlizszN	NVeySYM3W0GQR1XS
ATN-1	MlLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVm3T453UUN3ME2wMlg2OTF3IN88US=>	MknaV2FPT0WU
PLC-PRF-5	MonmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVfUWIVnUUN3ME2wMlg5PDd3IN88US=>	Mmj3V2FPT0WU
HT-3	M{fPZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV;JR\|UxRTBwOEm0NkDPxE1?	NWTOSnpbW0GQR1XS
MDA-MB-453	NUD5d5RGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUT1R5ZoUUN3ME2wMlkxOzB2IN88US=>	MnTqV2FPT0WU
HAL-01	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFTMbm9KSzVyPUCuPVk{PzlizszN	NX[yUIxUW0GQR1XS
NCI-H1993	NUfwflFoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3\lZWlEPTB;MT6wOFY2PyEQvF2=	NHzJdWZUSU6JRWK=
NCI-H2227	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NInQWolKSzVyPUGuNFQ6QDFizszN	MVzTRW5ITVJ?
LP-1	NX3WbpFoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2DzfGlEPTB;MT6wOlk{KM7:TR?=	M{TUUHNCVkeHUh?=
P31-FUJ	NIrRPVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVTJR\|UxRTFwMUC3OlYh\|ryP	M{Lk[3NCVkeHUh?=
NCI-H64	NUPI[FFFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3H6PWlEPTB;MT6xOVQzKM7:TR?=	MVfTRW5ITVJ?
SW1463	Mn;OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH7qNnlKSzVyPUGuNVg{PDlizszN	M{X6SXNCVkeHUh?=
SK-MEL-1	NX;HUYtDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlPXTWM2OD1zLkKwOVk2KM7:TR?=	M3ToeXNCVkeHUh?=
TALL-1	M1vqdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUjmVIhKUUN3ME2xMlI2OTZ3IN88US=>	NU\VcVVYW0GQR1XS
RO82-W-1	NVz0OVhzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWqzeldrUUN3ME2xMlM{OzN7IN88US=>	MXLTRW5ITVJ?
NCI-H1581	NUSxTFZDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYn0c5RnUUN3ME2xMlM2Pjh5IN88US=>	NGrzV\|dUSU6JRWK=
NCI-H748	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEnFUIVKSzVyPUGuN\|U4OzhizszN	M4jucXNCVkeHUh?=
HCC1187	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUS4eJpRUUN3ME2xMlU2PTJ{IN88US=>	NVjkcIVvW0GQR1XS
EoL-1-cell	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnXRTWM2OD1zLkW4PFg6KM7:TR?=	MX3TRW5ITVJ?
HuO-3N1	M{\2Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{jsW2lEPTB;MT64N\|QyOiEQvF2=	NGXuSIdUSU6JRWK=
NCI-H1793	NEfCOY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4PwWGlEPTB;MT64O\|U6OyEQvF2=	M2HoSXNCVkeHUh?=
Caov-3	MlzqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEjGZpdKSzVyPUKuNFA3OjVizszN	MXTTRW5ITVJ?
JAR	NH\SZYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MW\JR\|UxRTJwMEe5NkDPxE1?	MkjLV2FPT0WU
SK-MEL-28	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEPRUplKSzVyPUKuNVgxQThizszN	MUjTRW5ITVJ?
EM-2	NUDX[443T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn3vTWM2OD1{LkKwNlk{KM7:TR?=	M1qyNHNCVkeHUh?=
Mewo	NV;NbHFpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV\5S29EUUN3ME2yMlIzOjZ3IN88US=>	NF;EeWpUSU6JRWK=
NCI-H720	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFG0PGdKSzVyPUKuNlY2QDVizszN	Ml;WV2FPT0WU
CAL-54	M3n5U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF;FZ\|dKSzVyPUKuNlY4QTVizszN	NXe3[ZNXW0GQR1XS
MC116	MoW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2H3O2lEPTB;Mj6zOlM6PyEQvF2=	MX;TRW5ITVJ?
DG-75	NVzwbYc3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M17ybGlEPTB;Mj60PFU4PiEQvF2=	M4\McnNCVkeHUh?=
HCC1143	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1rHSWlEPTB;Mj61NFY2QCEQvF2=	MkDWV2FPT0WU
FTC-133	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHS3WmdKSzVyPUKuOVM3QDlizszN	NGmxcWFUSU6JRWK=
AsPC-1	MnroS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVjEOYc1UUN3ME2yMlU{QTJ7IN88US=>	M1PHPXNCVkeHUh?=
NCI-H889	M4[4fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVHld5g3UUN3ME2yMlU3PzB4IN88US=>	MofkV2FPT0WU
HT55	M37xSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mmf1TWM2OD1{Lk[yNFE6KM7:TR?=	MYXTRW5ITVJ?
UMC-11	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkTkTWM2OD1{Lke4O\|E2KM7:TR?=	M3zzSHNCVkeHUh?=
P12-ICHIKAWA	NHnVPJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFrPfWpKSzVyPUKuPFIxPDZizszN	M3OyUXNCVkeHUh?=
HCC1395	NYX1UoZMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml33TWM2OD1{Lkm4OlAzKM7:TR?=	NYrrUmI{W0GQR1XS
D-283MED	NGDoN4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{jIUGlEPTB;Mz6xPFk{PyEQvF2=	MWLTRW5ITVJ?
COLO-800	NVzJNJVST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXPyOmduUUN3ME2zMlM{QDl5IN88US=>	MXrTRW5ITVJ?
MFM-223	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mm\ITWM2OD1\|LkO2NFk4KM7:TR?=	NVjMZWVOW0GQR1XS
TE-5	M1PHVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVXJR\|UxRTRwNU[xOFch\|ryP	MYXTRW5ITVJ?
NCI-H209	NVfh[HpQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{TrT2lEPTB;ND63PFU4OiEQvF2=	NV;2RWVrW0GQR1XS
SiHa	NXTSV3F4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnOzTWM2OD12Lkm1NlA{KM7:TR?=	MY\TRW5ITVJ?
NCI-H1395	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2fUbGlEPTB;NT6xNFY{OyEQvF2=	MkT0V2FPT0WU
A498	NIrYbpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWTJR\|UxRTVwMkGyOVEh\|ryP	NVHN[YNOW0GQR1XS
ES5	M4rQcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoDiTWM2OD13Lk[xNVc5KM7:TR?=	MnnYV2FPT0WU
MDA-MB-157	M{TKcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXPJR\|UxRTVwNk[0OFMh\|ryP	Mn6wV2FPT0WU
NCI-H1623	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn6zTWM2OD13LkizOVU3KM7:TR?=	NH;XWZdUSU6JRWK=
RPMI-8866	NWOyN\|FFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH7qfpJKSzVyPUWuPFQ4QTJizszN	NVf5fopFW0GQR1XS
LC-1F	NVfYVlBVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIrQXGlKSzVyPU[uNFkzQTFizszN	NXTHTIhmW0GQR1XS
TCCSUP	M1nmU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2fsdWlEPTB;Nj62NFM1QSEQvF2=	NXfBNmJQW0GQR1XS
TT	MmTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn[xTWM2OD16LkOzNFA6KM7:TR?=	NGDuXIdUSU6JRWK=
NCI-H1838	NWLxfVVnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn\JTWM2OD16LkWxO\|MyKM7:TR?=	MYHTRW5ITVJ?
NCI-H322M	Ml3CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4qyNWlEPTB;OT6xOlI5OSEQvF2=	MkfGV2FPT0WU
NCI-H187	MnPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4XBO2lEPTB;OT61NVg{PSEQvF2=	NVrEOVRNW0GQR1XS
SBC-1	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXXu[VZTUUN3ME25Mlk{PjV4IN88US=>	NXXvUYlOW0GQR1XS
SCC-3	MmTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1rRemlEPTB;MUCuOVY4QSEQvF2=	M1HETnNCVkeHUh?=
SW948	MnHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGi0cIVKSzVyPUGwMlc2OTFizszN	NGLFRpdUSU6JRWK=
CPC-N	NWXpVo5ET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkjDTWM2OD1zMT6wNFch\|ryP	NWjae3pxW0GQR1XS
TGBC24TKB	MofsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmH4TWM2OD1zMz61Nlkh\|ryP	MkPoV2FPT0WU
NCI-H2452	NUnxVIZ6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4jYOmlEPTB;MUSuO\|Mh\|ryP	Mn32V2FPT0WU
Hs-578-T	NWXDT3YyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYHJR\|UxRTF6LkW3OVkh\|ryP	NULxWotoW0GQR1XS
DV-90	MkKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUKxSYkxUUN3ME2xPE46QTR3IN88US=>	M4PKPHNCVkeHUh?=
NCI-H1563	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWXYTpg2UUN3ME2xPU44QDh6IN88US=>	MkXhV2FPT0WU
SW780	MnjZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUPJR\|UxRTJzLkGzNVgh\|ryP	M3n1fHNCVkeHUh?=
NCI-H345	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn:5TWM2OD1{MT64O\|c6KM7:TR?=	MYrTRW5ITVJ?
LB771-HNC	NISx[4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4\JZ2lEPTB;MkKuOFgyOyEQvF2=	M3PGZXNCVkeHUh?=
RT4	MmDpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M17YTGlEPTB;MkOuN\|I5OiEQvF2=	NVfNT4NMW0GQR1XS
NCI-H82	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mnv6TWM2OD1{Mz61OVI3KM7:TR?=	M3:1dXNCVkeHUh?=
NCI-H524	MmGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn:2TWM2OD1{ND6zPFEzKM7:TR?=	NYP6PVVUW0GQR1XS
SNU-C1	NHrWXYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NG\yeXJKSzVyPUK0MlkyODVizszN	NEfPNnVUSU6JRWK=
NCI-SNU-16	MnnNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3jtVGlEPTB;NEiuN\|E1OiEQvF2=	NXPOTpNmW0GQR1XS

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-ALK / ALK / p-AKT / AKT / p-ERK / ERK / TβRI / TβRII; PubMed: 23993685 Mol Oncol Cells were treated with or without the indicated doses of 17-DMAG or AUY-922 for 3 h. Changes in ALK-related signaling and TGF-b receptors were analyzed using Western blot analysis. The densitometry values were determined relative to control of H2228 after normalization to b-actin protein. E-cadherin / Cleaved PARP / Bim; PubMed: 23993685 Mol Oncol Cells were treated with crizotinib (1 mM), 17-DMAG (1 mM), or AUY-922 (1 mM) for the indicated times. Cell lysates were subjected to Western blot analysis using the indicated antibodies. The densitometry values were determined relative to control after normalization to b-actin protein. HSP70 / Grp94 / Grp78 / p-eIF2α / CHOP / IRE1α / p-JNK; PubMed: 24796583 Oncotarget CCA cells were incubated with 0.5 uM NVP-AUY922 for 0, 2, 4, 8, 16, and 24 h. Whole cell lysates were subjected to western blot analysis for HSP70, Grp94, Grp78, p-eIF2α, CHOP, IRE1α, and phosphor-JNK. β-Actin was used as the loading control. CDK4 / HMGA2 ; PubMed: 26893968 PeerJ HCT116 cells were treated with NVP-AUY922 at the indicated concentrations for 48 hours. Cell extracts were analyzed using Western blotting with the antibodies for CDK4, Hsp70, and HMGA2, respectively.	23993685 24796583 26893968
Growth inhibition assay	Cell viability; PubMed: 26893968 PeerJ Cell viability assay was performed to determine the of HCT116 cells treated with various concentrations of NVP-AUY922 for 48 hours. p < 0.05, p < 0.01, **p < 0.001. All experiments were performed in three independent experiments.	26893968

In vivo

Treatment with NVP-AUY922 causes a robust antitumor response and inhibits p-Akt and VEGF expression in an HSC-2 xenograft model. ^[2] In BT474, NVP-AUY922 shows complete loss of ERBB2 and substantial depletion of ERα, in addition to reductions in CDK4 and phospho-ERK1/2. ^[3]

Protocol

Kinase Assay:^[3]	- Collapse Kinase assay: NVP-AUY922 is dissolved in DMSO at a concentration of 10 mM. NVP-AUY922 is assessed against HSP90α, HSP90β, GRP94, TRAP-1, HSP72, and topoisomerase II. Profiling against a panel of kinases has been carried out and screening against a panel of additional enzymes and receptors is performed at Cerep.
Cell Research:^[1]	- Collapse Cell lines: Human gastric cancer cells NCI-N87 Concentrations: 1 μM Incubation Time: 3 days Method: Human gastric cancer cells NCI-N87 (5-7 ×10³ in 50 μL/well) are seeded in 96-well plates and incubated at 37 °C for 24 hours, followed by NVP-AUY922 treatment for 1-3 days at 37 °C. After treatment, the cells are assayed by MTT method and analyzed by microplate reader. (Only for Reference)
Animal Research:^[3]	- Collapse Animal Models: Female NCr athymic mice bearing WM266.4 human melanoma xenografts Dosages: 50 mg/kg Administration: Administered via i.v. or i.p. (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	93 mg/mL warmed (199.76 mM)
	Ethanol	31 mg/mL (66.58 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 1% DMSO+30% polyethylene glycol+1% Tween 80 For best results, use promptly after mixing.	30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Luminespib (NVP-AUY922) SDF

Molecular Weight	465.54
Formula	C₂₆H₃₁N₃O₅
CAS No.	747412-49-3
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	AUY-922
Smiles	CCNC(=O)C1=NOC(=C1C2=CC=C(CN3CCOCC3)C=C2)C4=CC(=C(O)C=C4O)C(C)C

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2020-05-15)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT01772797	Completed	Drug: LDK378\|Drug: AUY922	Anaplastic Lymphoma Kinase (ALK)\|Non-small Cell Lung Cancer	Novartis Pharmaceuticals\|Novartis	June 2013	Phase 1
NCT01752400	Completed	Drug: AUY922	Non Small Cell Lung Cancer	Massachusetts General Hospital	January 2013	Phase 2
NCT01613950	Completed	Drug: AUY922\|Drug: BYL719	Stomach Neoplasms Esophageal Neoplasms Metastatic Gastric Cancer Mutated PI3KCA Protein Overexpressed HER2 Protein	Novartis Pharmaceuticals\|Novartis	December 2012	Phase 1
NCT01484860	Terminated	Drug: AUY922	Adenocarcinoma of the Pancreas\|Metastatic Disease	University Health Network Toronto\|Novartis Pharmaceuticals	January 2012	Phase 2
NCT01402401	Terminated	Drug: AUY922 + Trastuzumab	Advanced Gastric Cancer	Novartis Pharmaceuticals\|Novartis	November 2011	Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

HSP (e.g. HSP90) Signaling Pathway Map

HSP (e.g. HSP90) Inhibitors with Unique Features

Selective HSP90 Inhibitor

NVP-BEP800 : HSP90β-selective, IC50=58 nM.
Most Potent HSP90 Inhibitor

KW-2478 : HSP90, IC50=3.8 nM.
HSP90 Inhibitor in Clinical Trial

17-AAG (Tanespimycin) : Phase III for Gastrointestinal Stromal Tumors.
Newest HSP90 Inhibitor

XL888 : ATP-competitive inhibitor of HSP90 with IC50 of 24 nM.

Related HSP (e.g. HSP90) Products

PU-H71 ^New

PU-H71 is a potent and selective inhibitor of HSP90 with IC50 of 51 nM. Phase 1.
KNK437 ^New

KNK437 is a pan-HSP inhibitor, which inhibits the synthesis of inducible HSPs, including HSP105, HSP72, and HSP40.
VER155008 ^New

VER-155008 is a potent Hsp70 family inhibitor with IC50 of 0.5 μM, 2.6 μM, and 2.6 μM in cell-free assays for HSP70, HSC70, and GRP78, respectively, >100-fold selectivity over HSP90.
Tanespimycin (17-AAG)

Tanespimycin (17-AAG) is a potent HSP90 inhibitor with IC50 of 5 nM in a cell-free assay, having a 100-fold higher binding affinity for HSP90 derived from tumour cells than HSP90 from normal cells. Phase 2.

Features:Displays very low toxicity toward normal cells.
Ganetespib (STA-9090)

Ganetespib (STA-9090) is an HSP90 inhibitor with IC50 of 4 nM in OSA 8 cells, induces apoptosis of OSA cells while normal osteoblasts are not affected; active metabolite of STA-1474. Phase 3.
Alvespimycin (17-DMAG) HCl

Alvespimycin (17-DMAG) HCl is a potent HSP90 inhibitor with IC50 of 62 nM in a cell-free assay. Phase 2.

Features:A synthetic derivative Geldanamycin, with lower hepatotoxicity than parent antibiotic & higher potency and bioavailability than the similar derivative 17-AAG.
Geldanamycin

Geldanamycin is a natural existing HSP90 inhibitor with K_d of 1.2 μM, specifically disrupts glucocorticoid receptor (GR)/HSP association.
HSP990 (NVP-HSP990)

NVP-HSP990 (HSP990) is a novel, potent and selective HSP90 inhibitor for HSP90α/β with IC50 of 0.6 nM/0.8 nM.

Features:NVP-HSP990 is an orally available HSP90 inhibitor and is structurally distinct from other clinical HSP90 inhibitors.
Elesclomol (STA-4783)

Elesclomol (STA-4783) is a novel potent oxidative stress inducer that elicits pro-apoptosis events among tumor cells. Phase 3.
Onalespib (AT13387)

Onalespib (AT13387) is a selective potent Hsp90 inhibitor with IC50 of 18 nM in A375 cells, displays a long duration of anti-tumor activity. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Luminespib (NVP-AUY922)